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Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most prevalent 
neurodevelopmental disorders across the world. Currently, treatment for ADHD mostly 
consists of either medication or behavioral therapy or a combination of both. However, 
research has shown that medication used as therapy for the treatment of ADHD has side 
effects which parents deem undesirable for their children. Therefore, recent research has 
focused on patient and parent preferences. Studies have found that behavioral or other 
treatment options may often be chosen over medications. These same studies have 
documented the characteristics of parents that prefer certain treatments for their children. 
The purpose of this study is to investigate parent treatment preferences as it relates to 
medication and brain-based treatment options. The results of a treatment preference survey 
describe three groups of parents, Medication-Based, Brain-Based, and Open parents. 
Results were also indicative of certain factors that influence parent treatment choice for 
their children with ADHD. This study seeks to provide clinicians with a better 
understanding of patient and parent preferences, how to navigate presenting new treatment 
options, and to provide information on parents’ willingness to choose brain-based or other 
treatments for their children.  
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 Attention-Deficit/Hyperactivity Disorder (ADHD) is listed in the Fifth Edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) as a 
neurodevelopmental disorder that presents as persistent behaviors associated with 
inattentiveness, hyperactivity, and/or impulsivity (American Psychiatric Association, 
2013). When compared to the previous edition of the DSM (i.e., DMS IV), the updated 
criteria were broadened and the age of onset was increased to include symptoms in 
adolescents and adults to aid in the diagnosis of ADHD in older individuals. This 
disorder has been associated with poor academic performance and social and emotional 
difficulties in childhood and adolescence with prolonged difficulties in adulthood (Kofler 
et al., 2008; Rabiner et al., 2009; Wehmeier et al., 2010).  
Prevalence rates as reported by The Center for Disease Control and Prevention’s 
(CDC) National Survey of Children’s Health (2019), estimate that 6.1 million children 
between the ages of 2 and 17 years old have been diagnosed with ADHD. Of those 6.1 
million children, 64% presented with comorbid emotional, behavioral, or conduct-related 
disorders. Regarding treatment, 62% were prescribed medication, 47% were in 
behavioral treatment for symptoms of ADHD, and 23% were not receiving either 
treatment. More specifically, 32.5% of adolescents received medication only, while 
29.7% of adolescents received both medication and behavioral treatment. In a review by
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Danielson et al. (2018), the data from the CDC’s survey was further analyzed into 
specific demographics. It was noted that boys, adolescents between the ages of 12 and 17 
years old, Black children, non-Hispanic children, children in English speaking 
households, children living in homes within the lowest federal income bracket, children 
covered by public or both public and private medical insurance, children living in the 
Midwest or South, and those in rural areas were more likely to have received or currently 
have a diagnosis of ADHD. In comparison to previous years, there was a 57% increase in 
children ages 2-5 years old with ADHD.  
Treatment for ADHD has consisted largely of medication management, with two 
main types of medications, stimulants and non-stimulants, and behavioral treatments. 
Research has identified positive effects of medication use, including improvements on 
academic performance and behavioral functioning. Studies have also documented the 
effectiveness of behavioral treatments for symptoms of ADHD, especially in relation to 
long-term organization and planning skills. Behavioral treatments are recommended as 
first-line treatments for younger children (i.e., ages 2-5), while combinations of 
medication and behavioral therapy are recommended for children over the age of 6 
(Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on 
Quality Improvement and Management, 2011; Gleason et al., 2007). However, there are 
indications that research has generally failed in claiming superiority of one method of 
treatment versus the other (Rajeh et al., 2017). Furthermore, there is documentation of the 
negative impact of medication management for ADHD, such as loss of appetite, 
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insomnia, irritability, development of tic disorders, and misuse and distribution of 
medications (Efron et al., 1997; Lerner & Wigal, 2008; Rabiner et al., 2009).  
Although medication has dominated the field of ADHD treatment, other 
treatments have begun to receive the attention of research. Brain-based therapies, such as 
Neurofeedback (N.F.), have been investigated as alternative treatment options for ADHD. 
While NF is still considered to be an experimental treatment option for ADHD, research 
has found promising results in reducing the severity of ADHD symptoms and improving 
academic outcomes after a pre-determined number of sessions. Research has also 
suggested that the effects of N.F. last longer than those of medication even after the 
discontinuation of treatment (Duric et al., 2012; Gani, 2009). Previous studies have 
shown that a considerable number of parents have concerns over ADHD medications as a 
treatment option, especially when medication was the only option presented. One study in 
particular evaluated parent treatment choice in relation to different treatment components 
and found that parents responses fell into two groups, a medication avoidant group where 
parents were largely influenced by their desire to avoid medication; and outcome-
oriented parents whose choices were influenced by the outcomes they wanted for their 
children (Wacshbucsh et al., 2011). Wacshbucsh et al. (2011) strongly emphasized the 
importance of studying parent treatment preferences in order to improve the use and 
effectiveness of treatments as well as the outcomes for children and their families. 
However, the investigators also noted that parent treatment preferences may not be fixed 
and could change with the start and continuation of their child’s treatment, which 
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highlights the need to not only assess a parent’s treatment preferences initially in the 
treatment process, but also throughout the process. Therefore, assessing the parent 
preferences of the treatment of ADHD (e.g., medication based or behavioral based) is an 
important area of focus. The purpose of this study is to evaluate parent treatment choice 
of ADHD for their child(ren) in regard to medication or brain-based therapy through the 
use of a choice task. In this study, parents completed an ADHD knowledge questionnaire 
which was used to compare parent choices and their knowledge of ADHD. Then, parents 
were asked to read descriptions of two different treatment methods and indicate their 





Attention Deficit/Hyperactivity Disorder (ADHD) 
Attention Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental 
disorder that is seen across cultures and countries all over the world. ADHD is 
characterized by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, 
(DSM-5) as a persistent pattern of behaviors related to hyperactivity/impulsivity and 
inattention (American Psychiatric Association [APA], 2013). These symptoms must be 
present before the age of 12 but must be occurring consistently for at least the most recent 
six months. They must interfere with functional performance in at least two major 
settings, such as work, school, and home. There must also be a clear disturbance in the 
quality of either their occupational, academic, or social functioning, or a combination of 
some or all three of these aspects (APA, 2013). In academic settings, ADHD can inhibit a 
student’s ability to learn and impair social functioning (DuPaul & Stoner, 2014). Students 
with ADHD can demonstrate poor academic performance, experience rejection from their 
peers, and have difficulties inhibiting behavioral impulses (Pelham & Waschbusch, 
2004). Therefore, ADHD is typically seen in school-aged children due to the demands of 
the school environment. The DSM-5 states an individual’s presenting symptoms must not 
be better explained by another disorder and cannot co-occur with a psychotic episode or 
schizophrenia (APA, 2013). There are three main types of ADHD: Combined 
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Presentation, Predominantly Hyperactive/Impulsive Presentation, and Predominantly 
Inattentive Presentation. Symptoms of ADHD can change over time and therefore change 
the presentation of symptoms in the individual (APA, 2013). For example, an individual 
may experience a combined presentation of symptoms earlier in life, but as an adult may 
experience more inattentive symptoms. This highlights the importance of continued 
evaluation of the criteria throughout childhood, adolescence, and young adulthood.  
According to The Center for Disease Control and Prevention (CDC) in the United 
States in 2016, 6.1 million children, ages 2 to 17, had been diagnosed with ADHD. The 
CDC’s data also reports that in 2016, 62% of children diagnosed with ADHD were taking 
prescribed medication; 47% received behavioral treatment for ADHD, with that 
percentage increasing to 60% for children 2 to 5 years old; 23% were not receiving either 
treatment; and 64% had other emotional, mental, or behavioral disorders such as conduct 
disorder, anxiety, depression, autism, and Tourette syndrome (Danielson et al., 2018). 
More specifically, for adolescents, 32.5% received medication only and 29.7% received 
both medication and behavioral treatment. In a review by Danielson et al. (2018), the data 
from the CDC’s survey was further analyzed into specific demographics. Those that were 
more likely to have received or currently have a diagnosis of ADHD were boys, 
adolescents between the ages of 12 and 17 years old, Black children, non-Hispanic 
children, children in English speaking households, children living in homes within the 
lowest federal income bracket, children covered by public, or both public and private, 
medical insurance, children living in the Midwest or South, and those in rural areas. In 
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comparison to previous years, there was an increase of 57% of children ages 2-5 years 
old with ADHD. Further prevalence rates were specified in relation to severity as 14.5% 
reportedly presented with severe ADHD, 43.7% presented with moderate ADHD, and 
41.8% fell within mild ADHD. Of the sample, 63.8% had a comorbid disorder with 
behavioral or conduct-related disorders being most common as 51.5% presented with 
behavioral comorbid problems; and 32.7% had anxiety-related difficulties, 16.8% 
presented with depressive symptoms, 13.7% had autism spectrum disorder, and 1.2% 
presented with Tourette syndrome. In regard to medication use, a large portion of the 
sample, 62%, were reportedly currently taking medications, which accounted for 5.1% of 
all U.S children ages 2 to 17. The children more likely to be taking medication for the 
management of ADHD were non-Hispanic, primarily English speaking, and children 
living in the South. Statistical significance was noted among the ages of children taking 
medications. Specifically, children 2 to 5 years old were less likely to be taking 
medication than school-aged children and adolescents. In regard to behavioral treatment, 
46.7% with current ADHD received behavioral treatment. Several demographic 
differences were noted within those who received behavioral treatment. Younger 
children, boys, black children, and children with public insurance were more likely to 
have received behavioral therapy. Southern and Midwestern children in rural areas were 
least likely to have received behavioral treatment.  
Gender differences in ADHD are evident but not well described in the literature. 
Slobodin and Davidovitch (2019) noted that ADHD is more prevalent in boys than in 
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girls; however, this could be due to an under-identification of girls with possible ADHD 
due to the differences in symptom manifestation across the genders. Specifically, 
Biederman and Faraone (2004) found that girls with a diagnosis of ADHD present with 
more inattentive symptoms and less hyperactive/impulsive symptoms when compared to 
their male ADHD counterparts. Internalizing problem behaviors are usually more 
difficult for caregivers and teachers to identify. Boys with ADHD have been shown to 
present with comorbid externalizing behaviors and disorders such as conduct disorder, 
oppositional defiant disorder, and aggression, which quickly call the attention of 
caregivers and teachers as needing intervention or treatment. Slobodin and Davidovitch 
indicate that boys are more likely to have been diagnosed and treated for symptoms 
related to ADHD than girls. Male-to-female ratios for ADHD can range from 2:1 to 10:1 
(Novik et al, 2006; Ramtekkar et al., 2010; Willcutt, 2012). Slobodin and Davidovitch 
(2019) noted the lack of appropriate research studying the gender differences in ADHD. 
They described that previous studies have failed to include a suitable number of female 
participants and heavily relied on subjective measures of ADHD. The results indicated 
that parent and teacher reports showed that girls presented with significantly more 
inattentive symptoms than boys. However, no gender differences were noted in 
symptoms of hyperactivity and impulsivity. When considering objective measures of 
ADHD, in this case the Continuous Performance Task (CPT), gender differences were 
found as boys had higher impulsivity. However, no differences in performance (i.e., level 
of distractibility) were found between boys and girls. Another study by Ragnarsdottir et 
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al (2018) sought to find the gender and age differences in social skills in children with 
ADHD. Using subjective measures of social behaviors completed by parents and 
teachers, research collected social skill information on 592 children ages 5 to 10 and 215 
children ages 6 to 10. Results of the study suggested that girls continued to have peer 
problems in younger childhood and older childhood, as compared to boys who have more 
peer problems in younger childhood. Their data indicated that peer problems in boys 
tended to decrease as they got older.  
Recent studies on insurance and Medicaid eligibility of children with ADHD have 
shown steady increases in children with a diagnosis of ADHD. For example, Nyarko et 
al. (2017) describe the prevalence of children with medically managed ADHD and the 
differences in those with employer provided insurance coverage and those receiving 
public insurance (i.e., Medicaid). The researchers found that the prevalence of ADHD in 
children and adolescents with employer-provided insurance increased 2.2% from 2009 to 
2015. Rates increased 2% among ADHD children and adolescents with Medicaid in three 
years, from 2009 to 2012. These findings were reportedly similar to the studies 
investigating raising rates of ADHD diagnosis in general.  
Co-morbidity is common in those with ADHD (Jensen et al., 1997). A study 
conducted by Bird et al. (1993) provided data on the co-morbidity of ADHD and three 
other major diagnostic domains, which were conduct/oppositional disorders, depression 
disorders, and anxiety disorders. The data, originally collected for an epidemiological 
study on Puerto Rican children ages 4-16, indicated that in the children who met DMS-III 
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diagnostic criteria for ADD, 93% presented with comorbid conduct/oppositional 
disorders; 26.8% presented with symptoms of a comorbid depressive disorder, and 50.8% 
presented with comorbid anxiety disorders. As noted in the review by Jensen et al. 
(1997), a study conducted by Cohen et al. (1989) investigated rates of comorbidity 
among 93 children with ADD ages 9 to 18 years old, and found that 56% of those 
children presented with conduct disorder, 54% presented with symptoms of oppositional 
defiant disorder, 23% had an anxiety disorder, 24% had symptoms consistent with 
separation anxiety, and 13% presented with major depressive disorder.  
According to DuPaul and Stoner (2014), with an average of 20 students in every 
classroom in schools across the U.S., at least one student in every class can be or has 
been, diagnosed with ADHD. Furthermore, ADHD can impair students’ abilities to 
follow instructions, hence affect their schoolwork performance and completion. These 
students often have difficulties with organization, test performance, and study skills. In 
addition, they frequently disrupt the classroom atmosphere by engaging in impulsive 
behavior, such as talking out without permission, disturbing other students during group 
and independent work, and becoming expressively angry or frustrated when 
consequences for their behavior are given, or when faced with a difficult task (DuPaul & 
Stoner, 2014).   
  Students with ADHD often have difficulty with on-task classroom behavior. A 
comprehensive meta-analysis done by Kofler et al. (2008) found that, on average, 
students without ADHD are on-task 88% of instructional time, compared to those with 
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ADHD who are on-task 74% of instructional time. Studies show these students typically 
complete work at a lower rate than their non-ADHD peers, their work is often poor when 
compared to other students, and they have significant difficulties with staying on-task 
(Davies &Witte, 2000; DuPaul & Langberg, 1990; Frick et al., 1991). These off-task 
behaviors lead to a lack of attention to teacher instruction, leading to poor academic 
performance.   
Difficulties in school performance are not the only problems for students with 
ADHD. Wehmeier et al. (2010) summarize the social and emotional difficulties 
associated with ADHD. In their review, the authors describe those children with ADHD 
tend to have significantly weaker social and communication skills with family and peers 
when compared to neuro-typical children and adolescents. Furthermore, since ADHD is 
often comorbid with other behavioral disorders, those with comorbidities show to have 
greater social impairments than those with ADHD only. Also discussed in the review, is 
the emotional impairments of children with ADHD. That is, children and adolescents 
with ADHD have poor emotional self-regulation, intense emotional reactions of anger 
and aggression, difficulty acquiring adequate coping skills, and poor empathy skills. In 
2018, a study by Leaberry et al. sought to find the effect of comorbid internalizing 
disorders, and Oppositional Defiant Disorder (ODD) on the emotional regulation of 24 
children ages 7 to 10. The researchers measured the children’s respiratory sinus 
arrhythmia (RSA), a measure of the parasympathetic nervous system which also manages 
stress, as they completed a goal-blocked Card Sorting Task meant to induce stress and 
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frustration. The results indicated that children with ADHD and a comorbid internalizing 
disorder experienced greater stress and frustration as measured by the RSA when 
compared to a baseline phase. This study suggests a physiological component to 
emotional regulation in children with ADHD, indicating that the emotional regulation 
difficulties children with ADHD have can be linked down to a physiological level.  
Physiological mechanisms, such as sleep, are also impacted by children and 
adolescents with ADHD. In a review by Hvolby (2015), it was reported that individuals 
with ADHD often have difficulties with many aspects of sleep, including but not limited 
to, sleep latency, bedtime resistance, shorter sleep time, daytime sleepiness, night 
awakenings, and difficulty waking in the mornings. Furthermore, psychopharmacological 
treatments for ADHD can often exacerbate these sleep disturbances (Hvolby, 2015).  
Understanding the progression of ADHD from childhood into adulthood is vital in 
treatment planning, treatment effectiveness, and treatment choice. Research has 
documented the progression of ADHD into young adulthood and adulthood. Agnew-
Blais et al. (2016) documented the persistence, remission, and emergence of ADHD into 
young adulthood. Of the participants with ADHD in childhood, 21.1% continued to meet 
the diagnostic criteria for ADHD at age 18. Researchers found that continued symptoms 
of ADHD were associated with a higher severity of symptoms, lower cognitive abilities 
in childhood, higher levels of impairment in functioning, and increased rates of comorbid 
disorders at 18 years old when compared to those whose symptoms were in remission. 
Agnew-Blais et al. also found that individuals who were diagnosed with ADHD in 
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adulthood, did not meet the criteria for ADHD prior to age 12. These individuals were 
associated with having fewer behavioral difficulties and higher cognitive abilities at 18 
years old when compared to the ADHD persistent group. However, these individuals 
presented with similar symptoms, functional impairment, and rates of comorbid disorders 
when compared to the persistent group. Faraone et al. (2006) sought to examine the 
persistence of ADHD from childhood into adulthood. The study found that although the 
persistence of ADHD was highly dependent on the definition of persistence, there was a 
high rate of individuals experiencing ADHD “in partial remission” as noted in the DSM-
IV criteria, as it included about 65% of the sample. However, when the criteria were 
restricted to those participants that met full criteria for ADHD, prevalence of persistence 
declined to about 15% of the participants. This evidence suggests that symptoms of 
ADHD may lessen with age. In a more recent study by Holbrook et al. (2016), 
investigated the persistence of ADHD from childhood into adulthood and specified the 
role of ADHD presentation in the persistence of symptoms in a community-based 
sample. Results indicated that the prevalence of parent-reported inattentive symptoms 
counts did not change with age, but the highest count of hyperactivity/impulsivity 
decreased with age. Furthermore, individuals with a high count of 
hyperactivity/impulsivity and inattentive symptoms (i.e., a combined presentation), were 
more likely to continue to experience ADHD symptoms into adulthood. In general, this 
study found that those with inattentive symptoms experience more persistence of ADHD 
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into adulthood than those with just hyperactive symptoms as results showed a decrease in 
parent-reported hyperactivity/impulsivity. 
Neural Mechanisms of ADHD  
Research has identified that ADHD is caused by multiple factors, such as genetic 
and environmental risk factors. Curatolo et al. (2010) reviewed the etiology and 
neurobiological basis of ADHD. They cite genetic and environmental contributions on 
the development of ADHD. They also found substantial evidence in the association of the 
frontostriatal network (i.e., includes the lateral prefrontal cortex, dorsal anterior cingulate 
cortex, the caudate nucleus, and putamen), differences in the basal ganglia and other 
structures, and changes in cortical thickness in those with ADHD.  
A longitudinal study conducted by Shaw et al. (2006) studied the cortical 
thickness of 163 children with ADHD and 166 controls and their outcomes. The children 
underwent MRI assessment at least twice, once at baseline and again at follow-up. 
Outcomes were assessed using the Children’s Global Assessment Scale (CGAS). The 
study found that children with ADHD showed a general decrease in cortical thickness, 
also referred to as cortical thinning, and, at baseline, those with worse outcomes, 
specifically evidenced thinning at the left medial prefrontal cortex. Overall, cortical 
thinning in areas responsible for attentional processes, can lead to significantly poor 
attentional performance and worse outcomes than individuals with ADHD but minimal 
cortical thinning (Shaw et al., 2006). 
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A review by Emond et al. (2009) found substantial evidence linking the 
frontostriatal network of the brain with deficits in attention, hyperactivity, and 
impulsivity. This network encompasses the lateral prefrontal cortex, putamen, dorsal 
anterior cingulate cortex, and the caudate nucleus. The review also found growing 
evidence of malformations in the lateral ventricles, temporal lobe, parietal lobe, and 
occipital lobe of individuals with ADHD. Furthermore, reductions in the size, as 
measured by volume of specific brain areas has also been found. Shaw and Rabin (2009) 
also found evidence linking abnormalities in the basal ganglia, hippocampus, and 
amygdala, as well as the frontostriatal network. In their review, they found that children 
with ADHD may experience delays in cortical maturation, which leads to differences in 
development and changes in adolescence and on to adulthood.  
Medication treatment for ADHD can also alter brain functions, as is its purpose. 
For example, Clarke et al. (2001) studied the effects of stimulant medications on the EEG 
patterns of children with ADHD. The children’s baseline EEG levels were tested prior to 
starting a medication regimen. After a 6-month trail of stimulant medications, a second 
EEG was recorded. The researchers found that the ADHD group had significantly higher 
delta and theta brain activity prior to the start of stimulant medication. After the 6-month 
medication trial, children with ADHD had altered electrical brainwave patterns and 




Medication Management of ADHD  
The use of medication to manage symptoms of ADHD in children was first 
documented in 1937 by Dr. Charles Bradley, who used Benzedrine, also known as 
racemic amphetamine, to treat symptoms of hyperactivity and impulsivity (Bradley, 
1937). Since then, there has been a sharp increase in medication options for the treatment 
of ADHD, most of which consist of methylphenidates and amphetamines (Mayes & 
Rafalovich, 2007). This significant increase in medication use has recently been seen in 
the U.S. and European countries, where there was at least an 8.8% increase in medication 
use in children ages 10 to 14 years old in the years between 2005 and 2012 (Bachmann et 
al., 2017). In general, there are two types of medications for ADHD currently available, 
stimulant and nonstimulant medications. Within the class of stimulant medications are 
different types of stimulants, methylphenidate and amphetamine. Nonstimulant 
medications consist of medications that primarily treat other illnesses, but that have 
shown to help manage symptoms of ADHD (Southammakosane & Schmitz, 2015).  
Stimulant Medications 
The American Academy of Child and Adolescent Psychiatry (2013) suggest the 
use of stimulant medications as a first-line treatment for symptoms of ADHD. Results 
from the Multimodal Treatment of ADHD trial showed decreases in inattention, 
hyperactivity, and impulsivity, and improvements in disruptive behavior, academic 
performance, and social relationships. Furthermore, stimulant medications have shown to 
improve symptoms of depression, narcolepsy, aggression, and defiance (Jensen, 1999). 
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A review by Southammakosane and Schmitz (2015) sought to outline the 
medications commonly prescribed for ADHD and provide detailed information on the 
components of the medications and prescribing practices. They note that stimulant 
medications can be broken down into two different groups, long-acting and short-acting. 
Within the methylphenidates, a long-acting group, are drugs such as Focalin, Concerta, 
Ritalin, Metadate, Methylin, Daytrana, and Quillivant. Focalin, Ritalin, and Methylin are 
also noted in the short-acting drugs. The long-acting amphetamines include Vyvanse, 
Adderall, and Dexedrine. Short-acting amphetamine drugs include, Adderall, 
Dextroamphetamine, and ProCentra.  
Stimulant medications have been approved by the Food and Drug Administration 
(FDA) since April 2000, for use in children as young as 6-years-old, with certain 
amphetamines and dextroamphetamines having been approved for children as young as 
3-years-old. Generally, ADHD medications are prescribed starting with a lower dose and 
titrating as needed. Furthermore, if the desired response to the drug is not achieved, 
physicians can change the stimulant class starting with the same dosage and titrating until 
desired effect is maintained (Southammakosane & Schmitz, 2015; Stevens et al., 2013).  
Nonstimulant Medications  
Nonstimulant medications for ADHD usually consist of medications that are 
primarily used for the treatment of other conditions, with the exception of atomoxetine. 
These medications can be classified into six different classes: tricyclic antidepressants, 
non-tricyclic antidepressants, specific norepinephrine reuptake inhibitors, alpha-2 
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noradrenergic agonists, non-schedule stimulants, and others (Budur et al., 2005). 
Commonly prescribed for the management of hypertension, central a-agonists 
medications, guanfacine, and extended-release clonidine, have been found to be effective 
treatments for ADHD. These medications have been approved by the FDA for use in 
children as young as 6 years old. Southammakosane and Schmitz (2015) note that the use 
of alpha 2 agonists has shown reductions in defiant, hyperactive, and impulsive 
behaviors, and improvements in focus and sleep. However, prescribing practices of 
alpha-2 agonists require strict adherence to prescription instructions due to the potential 
of dangerous hypo- or hyper-tension reactions. Furthermore, with medications such as 
clonidine, administration of the drug at night is recommended due to its sedating effects.   
 Atomoxetine, also known as Strattera, is a norepinephrine reuptake inhibitor 
created specifically for the treatment of ADHD. Banaschewski et al., (2004) described 
atomoxetine as a “highly selective inhibitor of the presynaptic noradrenaline transporter” 
(p. 103). Although this drug has been approved for children as young as 6-years-old and 
has been shown to be effective for the ADHD population, a meta-analysis conducted by 
Schwartz and Correll (2014) found its effects inferior to that of stimulants and 
guanfacine. The most commonly prescribed nonstimulant medications are guanfacine, 
clonidine, and atomoxetine. 
Positive Effects of Medication Management for ADHD 
 The results of medication for the management of ADHD can show drastic 
changes in children’s behavior and academic performance. A recent meta-analysis, 
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including 40 studies on the effects of ADHD medications on functional outcomes, 
indicated that medication management of ADHD significantly lowered rates of mood 
disorders, suicidality, criminal behaviors, substance use, injuries and accidents, and 
traumatic brain injuries; and had a positive effect on educational performance (Boland et 
al., 2020).  
In a meta-analysis of double-blind placebo-controlled randomized trials with 
amphetamines or methylphenidates versus placebos, the authors sought to find the 
efficacy of these two medications for children and adolescents diagnosed with ADHD. 
Results of the analysis found that amphetamines significantly improved all ADHD 
symptomology over methylphenidates in children and adolescents. However, the study 
also noted significant publication bias in studies of methylphenidates, but not in those 
done on amphetamines (Faraone & Buitelaar, 2010).  
A systematic review and meta-analysis by Kortekaas-Rijlaarsdam et al. (2019) 
investigated the effects of methylphenidates on academic performance and accuracy in 
math, reading, and spelling. Analyses were conducted on thirty-four studies exploring the 
effects of methylphenidates on academic productivity and accuracy. All studies also 
included a placebo-controlled cross-over design. When compared to placebo groups, 
methylphenidates significantly improved accuracy and productivity in math. In reading, 
results indicated significant improvements in reading accuracy but not in productivity. 
Results were inconclusive for spelling accuracy and productivity. The researchers also 
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found that improvements in academic performance were small compared to overall 
improvement of ADHD symptoms in children prescribed methylphenidates.  
 Mikós et al. (2019) sought to study the executive function and attentional 
performance in children with ADHD compared to neuro-typical children. Three groups of 
participants were identified: medicated children with ADHD, treatment naïve children 
with ADHD who had never been treated with methylphenidate or atomoxetine, and 
neuro-typical children. Children receiving medication treatment for ADHD were 
prescribed methylphenidate or atomoxetine. Results indicate that the performance of 
medicated children was more closely aligned to that of the neuro-typical children, as no 
significant differences between their performances were found. However, treatment naïve 
children with ADHD generally performed worse on tasks of attention and executive 
functioning.  
Negative Effects of Medication Management of ADHD 
 Medication management of ADHD has shown significant improvements in 
symptoms and performance in children. However, with those improvements, studies have 
also documented the side effects and consequences of medication management. A study 
conducted by Efron et al. (1997) found that children prescribed methylphenidate and 
dexamphetamine were reported to experience insomnia, appetite suppression, irritability, 
tearfulness, anxiousness, sadness, and nightmares more so than prior to the start of 
medication. Furthermore, Banaschewski et al. (2004) found the following as possible side 
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effects: difficultly sleeping, loss of appetite, vomiting, nausea, fatigue, mood swings, 
dizziness, and constipation. 
Lerner and Wigal (2008) reviewed the most recent studies on the safety of long-
term stimulant use for management of ADHD symptoms. They reviewed articles which 
investigated the most common side effects of stimulant medication such as 
cardiovascular effects, growth, development of tic disorders, carcinogenic evidence, and 
effects on reproductive health. Overall, the review states that the studied negative long-
term effects of stimulant medications (i.e., elevated blood pressure, stunted growth, and 
development of tic disorders) were clinically significant for a minority of the participants 
prescribed stimulant medications.  
In 2015, Kidwell et al. conducted a meta-analysis to search the literature for the 
effects stimulant medications have on the sleep quality of children and adolescents with 
ADHD. The researchers specifically focused on children’s sleep latency, sleep efficiency, 
and total sleep time. The analysis included a total of nine randomized controlled trial 
studies that contained objective measures of sleep (i.e., actigraphy or polysomnography). 
The results found significant effects of stimulant medication on sleep latency as stimulant 
medication use was associated with longer sleep latency. Furthermore, results also 
indicated that medication dosage frequency was a moderator of sleep latency, suggesting 
that the more frequently the medication was taken throughout the day, the longer the 
sleep latency. Regarding sleep efficiency, the use of stimulant medications had a 
significant negative impact on sleep efficiency. However, the longer the use of the 
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medication the less negative the effect. Lastly, concerning total sleep time, there was a 
moderate effect between stimulant medication and total sleep time, indicating that 
children on stimulant medications experience shorter sleep time. 
Recent research has begun to show low strength of evidence for the use of 
psychopharmacological treatment of ADHD across all ages. A systematic review 
conducted by Charach et al. (2011) at the Agency for Healthcare Research and Quality 
found a low strength of evidence for the prescription of methylphenidate to 114 preschool 
children identified as at-risk for developing ADHD, and a presence of adverse effects on 
the children. Moreover, the researchers found low strength of evidence on the use of 
methylphenidate and atomoxetine for the reduction of ADHD symptoms and the presence 
of adverse effects. The 2018 update to this systematic review was unsuccessful at adding 
to the 2011 findings, indicating that the data has no changed significantly (Kemper et al., 
2018). 
Another issue that is evident in the use of medications for the treatment of ADHD 
is the non-prescribed or unintended use of stimulant medications. In the last decade, 
research has addressed the significant misuse of ADHD medications by college students 
as well as the self-treatment of attention problems by college students. Rabiner et al. 
(2009) examined the misuse and distribution to peers of prescribed ADHD medications. 
Participants consisted of 3,407 college undergraduates that were asked to complete a 
web-based survey. Of the 3,407 students, 156 students indicated that they had been 
diagnosed with ADHD; 115 of those diagnosed were prescribed ADHD medication. The 
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study shows that of the 115 students prescribed ADHD medications, 31% indicated 
taking their medication more often than prescribed, at a higher dose than prescribed, or 
using someone else’s medication. Regarding diversion of medications, 56% of the 115 
students with prescriptions reported being approached by other students to sell or give 
them their medication and 26% reported giving or selling their medications in the 
previous six months. These negative effects of ADHD medications have created 
impactful changes in the treatments available for ADHD and in the public perception on 
medication use. 
Assessing ADHD Through Brainwave Patterns 
Quantitative Electroencephalogram (QEEG) 
Electrical brain wave speed is measured by hertz (i.e., electrical frequency cycles 
per second) and they are divided into bands to delineate slow, moderate, and fast waves 
(Hammond, 2011). The four most researched brain wave bands are: Beta waves, Alpha 
waves, Theta waves, and Delta waves. Beta waves, measured at 12-30Hz, are the smallest 
and the fastest brainwaves associated with an alert state of mind; Alpha waves, measured 
at 7-12Hz, are characterized by slower and larger waves than Beta, and are associated 
with being in a relaxed state of mind. Alpha waves are known to be prominent in the 
posterior and occipital regions of the brain. Theta waves, measured at 4-8Hz, are 
characterized by slower and even larger waves than Alpha, and are associated with a 
dream-like state or mental inefficiency. Finally, Delta waves, measured at less than 4Hz, 
are the slowest and largest waves and are most prominent during deep sleep.  
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QEEG Indicators of Neurodevelopmental Disorders 
 QEEG indicators have been shown to be useful for the assessment of 
neurodevelopmental disorders because of the close association between behavior and 
EEG frequency (Snyder & Hall, 2006). For example, in clinical settings, QEEG has been 
used to identify children with ADHD (Loo & Barkley, 2005). QEEG indicators have 
shown that children with ADHD have greater theta activity and lower beta activity in the 
brain’s frontal regions than their non-ADHD peers when their eyes are open (Chabot et 
al., 2001) or when completing a task (Monastra et al., 2001). 
A study conducted by Monastra et al. (1999) focused on the use of QEEG for 
assessing the presence of ADHD in 482 participants. The researchers gave traditional 
ADHD assessments to identify those with ADHD, then separated participants into three 
groups: ADHD inattentive, ADHD combined, and control. Monastra et al. (1999) found 
that QEEG correctly identified 86% of the individuals who were found to have ADHD 
through the traditional assessments, while correctly detecting 98% of those who were not 
ADHD.  
Similarly, Clarke et al. (2001) investigated the presence of brainwave differences 
in a sample of 184 male children with ADHD. Participants were given full clinical 
assessments for ADHD then completed an eyes-closed resting state EEG using the 
international 10/20 system. Results indicated consistencies with past studies (Callaway et 
al., 1983; Clarke et al., 1998) as the ADHD group had an increase in theta and a decrease 
in relative alpha activity, an increase in theta/beta ratio, a decrease in frontal delta, and 
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increased frontal and central total power. The cluster analysis indicated three distinct 
groups of children with ADHD-C. Cluster 1 showed increased amplitude of theta activity, 
particularly in the frontal regions, while also showing a decrease in the amount of delta 
and beta activity. Cluster 2 demonstrated high levels of slow wave activity in delta and 
theta bands, with reduced fast wave activity. The largest differences between Cluster 2 
and the control group were found in the posterior and central regions. In Cluster 3, 
analysis indicated high power beta activity with decreased delta and alpha activity. In a 
previous study by Clarke et al. (2002), it was found that children with high levels of beta 
were more likely to have temper tantrums compared to other ADHD children with a 
profile of increased theta. Therefore, attention can be measured and identified using 
QEEG indicators, and these indicators have the capacity to reliably differentiate 
individuals that have attention disorders from those who do not. 
Neurofeedback and ADHD 
Neurofeedback (N.F.), or EEG Biofeedback, is the process of retraining brain 
wave patterns through operant conditioning (Hammond, 2011). N.F. uses frequency 
training, which involves single-channel referential or sequential EEG records at a pre-
determined number of electrode sites (Hammond et al., 2004). During training, patients 
watch a display on a computer screen and listen to feedback audio tones, which signal the 
reaching of a goal set by the experimenter (Hammond, 2005). Through this training, 
patients can adapt their brain waves into different electrical frequencies (Blanchard & 
Epstein, 1978; Heinrich et al., 2007; Kraft, 2006; Masterpasqua & Healey, 2003).   
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 It has been suggested that through N.F. training, some individuals with ADHD are 
able to gain self-control over physiological functions that are not usually consciously 
perceived (Heinrich et al., 2007). However, N.F. is still considered an experimental 
treatment option for this condition.  In a study done by Bakhshayesh et al., (2011) it was 
hypothesized that the improvements in the N.F. group would exceed those in the control 
group by measuring behavioral changes, as rated by parents and teachers, and 
improvements in cognitive performance tests. Also, those in the N.F. group would show 
decreased activity in theta and increased activity in beta waves, which are two of the most 
important brainwaves in those with ADHD. Thirty-eight children with ADHD, ages 6 to 
14, were recruited for the study and randomly assigned to either the neurofeedback group 
or control group. Treatment for both groups lasted for 10-15 weeks. Children in the N.F. 
group were training on increasing beta and decreasing theta frequencies with electrodes 
placed in CPz and FCz. The control group consisted of an alternative type of biofeedback 
training using electromyography (EMG) with electrodes placed on the frontalis 
musculature for EMG amplitude measurement. Analysis indicated that the overall results 
of the parent and teacher rating scales show significant improvements in ADHD related 
behaviors after treatments on all subscales of the parent ratings and in three of four 
subscales of the teacher ratings. However, Bakhshayesh et al., (2011) stated that they 
were unable to prove whether N.F. training was superior to EMG training when studying 
hyperactivity and impulsivity symptoms on rating scales.  
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 Lévesque et al. (2006) investigated the effects of N.F. training in children with 
ADHD on the neural substrates of the selective attentional processes involved in the 
Counting Stroop task. Participants were 20 children with ADHD randomly assigned to 
either the experimental group or control group. Those in the experimental group (N=15) 
received N.F. training, which consisted of enhancing beta amplitude and decreasing theta 
amplitude in phase one. In phase two, participants were trained to inhibit theta amplitude 
and increase the amplitude of beta waves. Participants in the control group (N=5) 
received no treatment. Results were presented in terms of pre- and post-test results. In 
Time 1, data were collected on the Counting Stroop task one week before training. In 
Time 2, data were collected from the Counting Stroop task one week after the training 
was concluded. It was shown that there were no significant differences between the 
groups in Time 1 when assessing average scores on Digit Span, The Connors Parent 
Rating Scale – Revised (CPRS-R), and the Integrated Vision and Auditory Continuous 
Performance Test (IVA). At Time 2, scores of those in the control group were not 
significantly different than their own scores in Time 1. However, for those in the 
experimental group, scores on the Digit Span and IVA were significantly higher, and 
scores on the Inattention and Hyperactivity domains of the CPRS-R were significantly 
lower at Time 2.   
 Gani (2009) presented the first randomized long-term follow-up study that 
provided data from N.F. sessions two years after the termination of treatment. Gani 
(2009) sought to find whether 1) after 2 years participants were able to maintain the 
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ability to self-regulate cortical activation, and 2) whether improvements in attention lead 
to differences in the stability of cortical self-regulation and clinical effects. During 
treatment, participants were randomly placed in two groups: Slow Cortical Potential 
(SCP) group and Theta/Beta group. At the two-year follow-up, participants in both 
groups were administered a N.F. session which involved a game with various trials in 
place. Generalization trials were implemented into the study to foster practice of self-
regulation in daily life, where no continuous feedback was provided during the session, 
only after the game was over. Results yielded significant findings in the Theta/Beta 
group; children who did not participate in the two-year follow-up exhibited significantly 
higher rates of ADHD symptoms than those who did participate. Results of behavior 
showed that the number of DSM-IV criteria for both inattention and hyperactivity 
declined significantly at the two-year follow-up. 
 Lansbergen et al. (2011) conducted a pilot study to test the safety and feasibility 
of using a double-blind placebo feedback-controlled design in studying the effects of 
individualized N.F. training on children with ADHD. Fourteen children, ages 8-15 years 
old, completed the study where eight children were randomly assigned to the EEG group 
and six assigned to the placebo group. Since N.F. training was individualized, protocols 
were determined based on visual inspection of the participants’ QEEG recording prior to 
treatment. Feasibility was assessed by adherence to attendance to the study and training 
sessions completed. Also, parents and children were asked whether they thought the child 
received N.F. training or a placebo. The safety of this design was measured by having 
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parents and children complete the Pittsburgh Side Effects Rating Scale (PSERS) before 
training and after 6, 10, 20, and 30 training sessions. The Sleep Disorders Questionnaire 
was used to assess for sleep problems. Efficacy of the training was measured by the total 
severity of inattention and hyperactivity/impulsivity symptoms, which were rated before 
training, during training, and 6 months after the termination of treatment. Results showed 
that all 14 children completed the study, and 2 out of 6 children and their parents, as well 
as one other child but not their parent, in the placebo group thought they received the 
N.F. training. Of the remaining children and parents, 75% in the active treatment group 
and 50% in the placebo group thought they received placebo training, which suggests that 
providing a placebo training as a control condition could be a feasible option to test the 
feasibility of N.F. When analyzing safety, neither of the conditions presented significant 
adverse side effects on sleep, suggesting that N.F. and a placebo training condition can be 
safe approaches. Although there was clinical improvement over time in ADHD 
symptomology, there were no significant differences between the EEG N.F. training 
condition and the placebo training condition. This suggests that individualized N.F. 
training did not exceed the placebo training group in clinical improvement on ADHD 
DSM-IV symptomology.   
Duric, Assums, Gundersen, and Elgen (2012) recognized the immense lack of 
controlled studies, stating that while other studies used other treatments or waitlists as 
control groups, randomized control studies are still needed in the field. The objective of 
the study was to investigate the effectiveness of N.F. on the core symptoms of ADHD, 
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including attention and hyperactivity. Participants were 91 children and adolescents, ages 
6-18, with a diagnosis of ADHD. Participants were randomly assigned to either the 
neurofeedback group, N.F. plus medication group, or only medication group. Those in 
the N.F. group were training to enhance beta and inhibit theta. Sessions were done three 
times a week, lasting 40 minutes, with 30 sessions for each participant. The pre- and post-
evaluations consisted of five-minute baseline periods in the form of alpha training. In the 
N.F. plus medication group, neurofeedback protocols were identical to the neurofeedback 
group protocols. The medication taken in the N.F. in addition to medication group and 
medication only groups was 1 mg of methylphenidate taken twice per day as 
recommended. Parent reports showed an improvement in the core symptoms of ADHD in 
the N.F. group. Those in the N.F. plus medication group showed similar improvements. 
N.F. had an effect on improving attention and hyperactivity symptoms in the participants. 
No significant differences were found among the three treatment groups in the 
improvement of core symptoms of ADHD, suggesting that the effects of N.F. can be 
close to that of stimulant drugs. This study supports the use of N.F. as a less invasive 
treatment option for those with ADHD, especially the 20% of the ADHD population that 
do not respond to stimulant medication.   
 Steiner et al. (2011) investigated the effects of two computerized training 
programs on teaching children with ADHD to attend better. Participants were 41 children 
with ADHD from two middle schools. They were randomly assigned to a N.F. group 
which received two sessions a week: a) the attention training through a standard 
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computer format (SCF) group, where the participants completed visual and auditory 
activities designed to reduce impulsivity and increase attentiveness, or b) the waitlist 
condition, which received no treatment until after the post-intervention assessments were 
completed. In the N.F. training group, children were trained to decrease theta frequencies 
and increase beta frequencies. The Connors Rating Scales – Revised (CRS-R), the 
Behavior Assessment Scales for Children (BASC), and the Behavior Rating Inventory of 
Executive Functions (BRIEF) were used as outcome measures. Results were mixed, 
showing that students in the waitlist condition reported significant change on the CRS-R 
ADHD Index, and those in the SCF condition reported significant change on the BASC 
Attention Problems Scale. When analyzing observed behavior, those in the N.F. group 
showed a trend toward lower levels of fidgeting and off-task behaviors. However, there 
were no significant findings. Parents whose children were in the N.F. condition reported 
significant changes on all three CRS-R and the two BASC subscales. In the SCF 
condition, parents reported significant changes in the CRS-R Inattention and ADHD 
Index, BASC Attention Problems, and BRIEF. Overall, Steiner et al. (2011) show the 
difficulty of maintaining reliability when conducting N.F. sessions outside of the clinical 




 Public perception can be defined as a social construct where the opinion of a 
group of people is collected by asking for their preference or thoughts on particular topics 
and used to create a multitude of services and products (Dowler et al., 2006). Public 
perception is assessed in almost every industry worldwide and drives the creation and 
modifications of policies, technology, education, and more.  
In recent years, research focused on the public perception of mental health across 
many ages and cultures. Evaluating public perceptions of mental health treatments can 
aid in the marketing, creation, and improvement of potential and existing treatment 
methods. Therefore, most of this research has revolved on how to change the negative 
perceptions that the public holds concerning individuals with mental health illnesses and 
the stigma of seeking services. For example, Gaebel et al. (2006) studied the relationship 
between the severity of mental illness and the stigma, or public perception, of that illness. 
The researchers analyzed studies that used attitude surveys towards diagnostic labels and 
other aspects of mental health. In their review, they found that public perception changed 
depending on the diagnostic label and the psychosocial disability.  
In 2007, Vogel et al. investigated the links between perceived public stigma and 
willingness to seek mental health therapy. The participants consisted of college students 
enrolled in a psychology course. Participants completed the Perceived Devaluation-
Discrimination scale, Self-Stigma of Seeking Help Scale, Attitudes Toward Seeking 
Professional Psychological Help Scale, and the Intentions to Seek Counseling Inventory. 
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Results indicated that perceived public stigma is positively associated with self-stigma, 
self-stigma is negatively related with individuals’ attitudes concerning counseling, and 
the attitudes are positively related to the willingness of individuals to seek therapy. In 
other words, as public stigma increases, or becomes more negative, so does self-stigma; 
and as self-stigma increases, attitudes or willingness to seek counseling decreases. The 
researchers stated that although it is difficult to change public perception of mental health 
services, knowledge of the mediators between stigma and willingness to seek help can aid 
in the development of alternative, practical, and more efficient treatments.  
In an effort to investigate parents’ willingness to use psychiatric medication for 
the treatment of mental health illness in children, Pescosolido et al. (2007) found 
substantial evidence that parents have significant concerns of the stigma surrounding the 
treatment of children with mental health needs. Most of the study’s sample (68%) 
indicated that they believe physicians over-medicate children, and 45% reported that a 
child with mental health needs would experience alienation or rejection in school. Results 
also indicated that 35% of the participants believed parents experience self-stigma as a 
result of their child’s mental health needs. The researchers discuss the importance of this 
information for the development of future treatment options and for mental health and 
medical professionals to be prepared when confronted with skepticism. There are 
significant concerns that stigma associated with children’s mental health and the 
treatment, especially regarding medication, present as a barrier to seeking and being 
willing to engage in mental health treatment.  
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Assessing Parent Perception of ADHD 
In 2003, a study on parent perceptions and satisfaction with medication for 
ADHD found that over half of the sample was hesitant to trying medication management 
for their children due to public information on medications. Researchers also found that 
parents were generally misinformed on ADHD medication treatment and stated that more 
information is needed on perceptions of ADHD medications and the differences among 
race/ethnicity, income, and social status (DosReis et al., 2003).  
A study by Bussing et al. (2012) investigated the ADHD treatment perceptions of 
adolescents, parents, healthcare professionals, and teachers. They studied each group’s 
views of two pharmacological and three psychosocial treatment methods and their 
willingness to participate in all five treatments. Results indicated that adolescents showed 
significantly lower desire to engage in any treatment for ADHD. Parents and healthcare 
professionals indicated more willingness towards employing/recommending counseling 
than teachers. Regarding the use of short-acting or extended-release ADHD medications, 
short-acting medications were associated with negative attitudes. However, extended-
release medications did not have a negative association. Overall, short-acting medications 
were generally viewed more negatively as parents, teachers, and adolescent respondents 
associated them with a negative stigma, physiological and psychological side effects, and 
a greater possibility of future drug dependence, more so than long-lasting medications.  
DosReis et al. (2003) conducted a survey study examining parental perceptions 
and satisfaction of stimulants as a treatment for ADHD. This study found that around 
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55% of parents were at first hesitant for their child to use medication due to the 
information in the media, and 33% reported that they believed too many children are 
prescribed medication for ADHD. Parents also reported being more satisfied with their 
child’s academic and behavioral improvement more so than any improvements in their 
child’s self-esteem.  
In 2016, Wymbs et al. used a Discrete Choice Experiment to assess parent 
preferences between group parent training or individual parent training programs and 
how their preference would affect their participation in the training. The study found that 
over half of the sample (58.7%) preferred individual parent training and were more 
interested in trainings that would help them understand their child and their problems 
with ADHD instead of a training that would solve their child’s problems. 19.4% of 
parents in the sample reported being most interested in group parent training programs 
that would help them build the skills needed to solve the problems their child 
experiences. Of particular interest was the 21.9% of parents that fell in what the study 
labeled Minimal Information, meaning the parents did not choose either training option. 
These parents reported that their child presented with the highest levels of depression and 
most severe mental health concerns. The researchers indicated that their results show a 
need to consider alternative therapy formats for parent trainings for families that 
experience high levels of stress due to the symptoms of ADHD coupled with other life 
factors.  
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A study by Fegert et al., (2011) sought to examine parent treatment choice for 
their children with ADHD using a Discrete Choice Experiment as it relates to medication. 
More specifically, the study was to evaluate what therapy attributes were most important 
to parents. The researchers used both qualitative and quantitative measures to assess what 
factors influence a parent’s choice. The study analyzed the self-administered surveys of 
121 parents of school-aged children. The survey generally assessed what attributes and 
outcomes of the treatment were most important to the parents. There were 23 total 
attributes included in the Discrete Choice Experiment. However, the attributes were 
condensed down to six general attributes. The six attributes were duration of action of the 
treatment, whether whole-day or half day; side effects; dosage of the product; discretion 
of use of the treatment; emotional situation; and social situation. Results found that 
parents assigned importance to all six attributes as they were all statistically significant. 
However, the improvement of their child’s social performance was the most important 
treatment attribute to the parents surveyed. The second most important attribute was an 
improvement in emotional functioning and long-acting effectiveness of medication. The 
results also showed that the least important attributes for parents were the side effects of 
the treatment as long as they did not interfere with the social and emotional functioning 
of their child.  
In 2011, Waschbusch et al. examined the treatment preferences of 183 parents of 
children with ADHD that were not being treated with medications. Parent preference was 
assessed using a discrete choice task where parents were presented with brief descriptions 
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of the three treatment choices along with possible side effects and risks. Parents chose the 
treatment they would prefer their child to receive. According to the results, parents could 
be clustered into two groups, Medication Avoidant (70.5% of parents), who were mainly 
driven to avoid medication use for their child, or Outcome Oriented (29.5% of parents), 
who were more focused on alleviating their child’s problems. This study also found 
specific demographic differences in the groups. Parents in the Outcome Oriented group 
were more likely to be single parent, had few years of education, lower socioeconomic 
status, higher reported stress, and depression, and had behaviorally challenging children. 
Using data simulators, Waschbusch et al., (2011) were able to determine what treatments 
parents would likely choose. They found that most parents would have rejected 
medication only options and instead heavily considered behavioral treatment only or 
combined medications and behavioral treatment options. The results demonstrate that 
even when presented with multiple options, parents show a preference for non-
medication treatment.   
Summary and Study Rationale 
 ADHD is associated with a variety of academic, social, and occupational 
problems such as difficulties retaining educational information, difficulties controlling 
emotional and behavioral impulses, and problems keeping up with daily demands. Since 
1937, the use of medication management has been the most widely used treatment for 
ADHD. Medications for ADHD include stimulants and non-stimulants, each with their 
own drug classes. Stimulant medications (i.e., methylphenidates and amphetamines) are 
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the most frequently prescribed and have been associated with positive effects on reducing 
ADHD symptomology. Non-stimulant medications (i.e., drugs primarily used to treat 
other illness and atomoxetine), have also been found to have similar effects, but not as 
potent effects as stimulant medications. However, in the last decade there has been a 
plethora of studies focusing on the negative effects of medication treatment for ADHD. 
Studies have shown that stimulant medications can have short-term and long-term side 
effects that many parents find highly problematic (e.g., sleep disruptions, appetite 
suppression, growth impairments, higher probability of substance use later in life, and 
mood disruptions).  
Due to these undesirable effects of medication management for ADHD, other 
treatment options have become available. Brain-based treatment such as N.F. is one of 
these options. Although still considered an experimental treatment, a decade of research 
has found promising results in reducing ADHD symptomology. Studies have documented 
reductions in hyperactivity, impulsivity, and inattention while also being able to maintain 
these reductions long after the discontinuation of treatment, with a few “booster sessions” 
conducted periodically.  
Parent perceptions on the treatment of ADHD indicate a significant gap in the 
treatments available, as most parents believe there are limited treatment choices. Studies 
show that parents are generally weary of medication management for ADHD, and imply 
that some parents feel as if they have very limited choices for the effective treatment of 
ADHD. Currently, there are few studies that evaluate parent perceptions of brain-based 
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treatment options. Additionally, there is limited research that studies the public 
perception of neuromodulation as a treatment option in general. Therefore, the purpose of 
this study is to 1) evaluate parent treatment choice of ADHD in regard to medication or 
brain-based treatment; 2) to evaluate the viability of brain-based treatment from a parent 
perspective; 3) to assess the variables that influence parents’ choices; and 4) to help 
clinicians build brain-based practices and aid in the effective marketing of brain-based 
treatments to parents of children with ADHD. 
Hypotheses 
The following are the specific hypotheses that will be tested in this study: 
I. When compared to brain-based treatment, parents will be predominantly 
medication oriented due to its low cost, easy administration, and quicker response 
to treatment. 
II. Based on the findings by Waschbusch et al. (2011), it is hypothesized that 
although insignificant, a large number of parents will fall in the brain-based 
oriented group due to a high number of parents that are against medication 
management for ADHD.  
III. Parents who score higher on the AKOS-R (i.e., have more knowledge of ADHD) 








The current study had a total sample of 203 participants. Participants were 
recruited via online social media parent groups for children with ADHD (See Appendix 
A for list of social media groups used). For this study, 137 parents of children with 
diagnosed ADHD inattentive, hyperactive/impulsive, and combined presentations 
completed the survey in its entirety. Participants were excluded if they did not complete 
the survey in its entirety (N=66). Participants consisted of mostly female caregivers 
(97.8%). The majority of the sample’s children (82.5%) were receiving treatment for 
ADHD. Age of the parents who participated ranged from 21 years old to 59 years old. 
The sample was mostly white (86.1%) and had a bachelor’s degree (35.8%). The majority 
of the sample had not been personally diagnosed with ADHD (83.2%). See Appendix B 
for descriptive statistics for the study’s sample. In the autoclustering analysis, the best 
representation of the sample for the 135 participants was the three-cluster solution.  
Measures 
A brief demographics survey was presented to assess for possible extraneous 
variables, exclusion criteria (i.e., not having a child diagnosed with ADHD), and to 
gather demographic information on parents and their children.  
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Participants were presented with a survey assessing treatment preferences of 
ADHD. Participants had two treatment options to choose from: 1) medication use; and 2) 
neuromodulation techniques, specifically Neurofeedback. Participants received The 
ADHD Treatment Choice Task for Parents. This task is a modification of the choice task 
developed by Waschbusch et al. (2011). The task includes brief descriptions of each of 
the treatment components: – describing the techniques and procedures that could be used 
in the treatment, and treatment outcomes; – describing any changes that could result from 
the treatment, and side effects; and – describing negative effects and costs of treatment 
(Appendix C). 
The ADHD Treatment Choice Task for Parents was assessed through a pilot study 
using 10 doctorate-level graduate students enrolled in a Southwestern university. The 
results of this pilot study can be found in Appendix D. The results show that the majority 
(90%) of respondents may regret the treatment choice if the child experiences long-
lasting side effects. Conversely, 60% of respondents reported that short-term side effects 
would not make them regret their treatment choice. Half of the sample indicated that they 
would spend $50 to $500 a month on long-term treatments, while 10% said they would 
spend $1200 a month on treatment, as long as the treatment did not last longer than six 
months. In 70% of the respondents, insurance coverage would influence the treatment 
choice. Concerning scientific validity, 90% of the sample indicated that they would only 
choose a treatment options that has strong scientific evidence. 40% of the sample 
reported they would like the treatment to have some sessions with the treatment provider, 
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and 60% stated they would like the treatment to include a therapeutic component. 
Regarding immediate changes in behavior, 80% of the sample indicated that it is not 
important for their child to experience immediate changes, as long as they were assured 
that changes would occur later. The majority of the sample (44.4%) reported that when 
symptoms are no longer observed, they would prefer their child not need further 
treatment other than booster sessions. Regarding child awareness and treatment 
components, 90% of respondents stated that it was important for them to choose a 
treatment that would help the child become more aware of their condition, 77.7% stated 
that their child would take a low dose of medication, and 77.7% also endorsed that their 
child would attend some sessions of brain-based treatment.  
The Attention-Deficit/Hyperactivity Disorder Knowledge Scale – Revised 
(AKOS) was used to assess parents’ knowledge of ADHD and effective treatments. The 
AKOS is a 43-item true/false survey designed to measure parent knowledge of and 
attitude towards ADHD and various evidence-based treatment options (Appendix C, 
Figure 2). Parents completed only the first 17 items as this comprises the Knowledge 
Scale (Owen Currier, 2004).  
Procedure 
After providing their Informed Consent, participants completed a demographics 
survey to document if they are a parent of a child with ADHD, their gender, age, 
ethnicity, years of education, whether their child is receiving treatment for ADHD, and 
whether they as parents have been formally diagnosed with ADHD. After completion of 
43 
 
the demographics survey parents completed the AKOS-R where they were asked to 
indicate their belief on whether various statements about ADHD were true or false.  
Participants were then presented with the choice task which was comprised of 
brief descriptions of each treatment option; descriptions included the costs, side effects, 
and possible outcomes. Participants choose their preference as it related to side effects, 
costs, scientific validity, treatment sessions, therapeutic components, immediate changes, 








 The present study is an exploratory design consisting of mixed methods of 
quantitative measures (i.e., Cluster Analysis) and qualitative measures (i.e., description 
on clusters). To analyze the data of this study’s exploratory design, a variety of statistical 
analyses were conducted. Statistical analyses were conducted using the IBM SPSS 
program. To reduce Type I error, this study used a p<.05 significance level. Totals and 
percentages for the sample were collected and used for overall analyses (See Appendix 
B). A Cluster Analysis was conducted to identify potential groups or clusters of parents 
within the responses to the Treatment Choice Task for Parents. Cluster Analyses are used 
in exploratory research to find groups within data. The groups are not assigned needing in 
terms of dependent and independent variables and must be assigned meaning in a 
descriptive fashion (Field, 2013). A factor analysis was also conducted on the Treatment 
Choice Task for Parents to ensure differentiation between the items within the task. 
Factor Analyses aid in identifying whether questions or items of a task or questionnaire 
are different or similar to one another. This analysis is important to establish reliably of a 
measure’s individual items. For the purposes of this study, the factor analysis also serves 





Defining the Number of Clusters. An exploratory two-step cluster analysis was 
conducted using each item of the ADHD Treatment Choice Task for Parents. The 
autoclustering function from SPSS was used to find the best cluster solution. The SPSS 
autoclustering functioning selects the lowest information criterion measure as the best 
solution (the Schwarz Bayesian Information Criterion; BIC) and the highest ratio of 
distance measures (RDM; “SPSS 14”, 2005). An Autoclustering solution is affected by 
the order of the data (Milligan & Hirtle, 2003). Therefore, the full data set was ordered by 
the participants’ IP addresses alternating in an ascending and descending fashion. Results 
showed two optimal numbers of clusters, those being the three- and four-cluster 
solutions. There was not a substantial difference in variance between the three (BIC = 
3872.6) and four (BIC = 3863.1.7; RDM = 1.0) cluster solution. Therefore, the three-
cluster solution was chosen as the distribution of data is best explained within three 
clusters for the three choice options within the ADHD Treatment Choice Task for 
Parents.  
A Chi-Square analysis aided in explaining if the distribution of the results of this 
study (i.e., study’s sample) statistically differed from the expected distribution (i.e., 
population). This analysis was chosen to identify differences between the two categorical 
variables in the study (i.e., medication-based or brain-based). Upon inspection of the chi-
square results for the three- and four-cluster solutions, the four-cluster solution was 
removed from formal analyses as the three-cluster solution best explains the distribution 
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of the data. However, the four-cluster solution analyses are provided for review in 
Appendix E.  
As seen in Table 1, 88.1% of respondents in Cluster 1, 93.5% of respondents in 
Cluster 2, and 66.7% of respondents in Cluster three reported that their child was 
currently receiving treatment for ADHD, suggesting that Parents in Cluster 3 were less 
likely to have their children in treatment for ADHD. Parents in Cluster 2 reported having 
their children in treatment more so than parents in Clusters 1 and 3. Furthermore, 
although not significant, Cluster 2 had the highest percentage of parents diagnosed with 
ADHD (i.e., 22.6%) and parents in Cluster 3 (i.e., 8.9%) were less likely to have been 
diagnosed with ADHD themselves. There were no significant differences in education, 
gender, and race/ethnicity between the clusters.  
Table 1 
Chi-Square Demographics Results for the Three-Cluster Solution 















18.6 22.6 8.9 2.95 NS 
Table 1 Continued…  
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Diploma/GED 10.2 6.5 11.1   
Associate’s 
Degree 
16.9 16.1 4.4   
Bachelor’s 
Degree 
28.8 29.0 48.9 10.46 NS 
Master’s Degree 25.4 32.3 28.9   
Doctorate/advan
ced degree 
18.6 16.1 6.7   
Gender      
Female 98.3 93.5 100 
3.65 NS 
Male 1.7 6.5 0.0 
Race/Ethnicity  
Hispanic 5.1 12.9 8.9 
7.50 NS 
Black 3.4 3.2 0.0 
White 89.8 80.6 84.4 
Asian 0.0 0.0 4.4 
Other 1.7 3.2 2.2   
 
Presented in Table 2 are the results of the chi-square analysis on the Treatment 
Choice Task for Parents.  
Long-Lasting Side Effects: Significant differences between the clusters was 
evident at the less than .001 level. Specifically, 86.4% of parents in Cluster 1 reported 
that long-lasting side effects may make them regret the treatment choice. In Cluster 2, 
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64.5% reported that the side-effects would not make them regret the treatment choice. In 
Cluster 3, while the distribution was slightly more even, 46.7% of parents reported that 
long-lasting effects would significantly make them regret the treatment choice.  
Short-Lasting Side Effects: Significant differences between the clusters were 
noted. In Cluster 1, 57.6% of parents reported they would not regret the treatment due to 
short-lasting side effects. In Cluster 2, 61.3% of parents said they would not regret the 
treatment due to short-lasting side effects. In Cluster 3, 44.4% of parents reported that 
short-lasting effects may make them regret the treatment choice.  
Cost: There were significant differences between the clusters at the less than .001 
level. In Cluster 1, 72.9% of parents indicated that they would pay $15 to $500 a month 
on long-term treatments. In Cluster 2, 71.0% of parents reported that they would pay $15 
to $500 a month as well. In Cluster 3, 57.8% of parents reported that cost would not 
influence their choice of treatment for their child.  
Insurance coverage: There were no significant differences between the clusters. In 
all three clusters, the majority of parents (i.e., 76.3% in Cluster 1, 64.5% in Cluster 2, and 
71.1% in Cluster 3) reported that insurance coverage may influence their choice of 
treatment for their child.  
Scientific Validity: There was no significant difference between the clusters. The 
majority of parents in all three clusters (i.e., 67.8% in Cluster 1, 87.1% in Cluster 2, and 
64.4% in Cluster 3) reported that they would choose a treatment choice with high 
scientific validity.   
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Sessions with Provider: Significant differences between the clusters were found at 
the less than .001 level. In Cluster 1, 93.2% of parents and in Cluster 2 54.8% of parents 
wanted their child to have some sessions with the treatment provider. In Cluster 3, 48.7% 
of parents wanted weekly sessions with the provider.  
Therapeutic Component: There was a significant difference between the clusters. 
Within Cluster 1, 84.7% of respondents would like there to be a therapeutic component to 
treatment but it is not a requirement. In Cluster 2, 54.8% of parents also would like a 
therapeutic component but is not required. In Cluster 3, 57.8% of parents require a 
therapeutic component to their child’s treatment.  
Immediate Changes: Results indicate a significant difference between the clusters. 
78.0% of parents in Cluster 1 indicated that immediate changes are not important if there 
is assurance that their child’s behavior will improve. In Cluster 2, 58.1% of parents 
reported that immediate changes in behavior are important. In Cluster 3, 80% of parents 
also reported that immediate changes are not important if there is assurance that their 
child’s behavior will improve.  
Continuation of Treatment: Significant differences were noted at the .05 
significance level. Across all three Clusters, the majority of parents in each cluster (61.0 
%, 38.7%, and 40.0%) reported that they do not want to continue treatment when 
symptoms are no longer observed.  
Awareness of Condition: Results indicate significant differences between the 
group at the .001 level. In Cluster 1, 2, and 3, a majority of parents (76.3%, 93.5%, and 
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93.3% respectively) reported that they want their child’s treatment to help their become 
aware of their condition of ADHD.  
Medication Treatment: A significant difference between the clusters was present 
at the less than .001 level. In Cluster 1, 91.5% of parents reported that their child would 
likely receive a low dose of medication. In Cluster 2, 51.6% of parents indicated that their 
child would likely receive a high dose of medication. In Cluster 3, 68.9% of parents also 
reported that their child would likely receive a low dose of medication.  
Brain-based Treatment: Results showed significant differences between the 
clusters at the less than .001 level. The majority of parents in Clusters 1 and 3, 66.1% and 
55.6% respectively, reported that their child would likely complete some sessions of 
brain-based treatment. In Cluster 2, 71.0% of parents reported that their child would not 
attend brain-based treatment sessions.  
Overall, the data shows certain characteristics of parents within each Cluster. 
Parents in Cluster 1 fell generally within the middle of the groups as they were more 
likely to have their child in treatment when compared to Cluster 3, but less likely than 
Cluster 2. Additionally, parents in Cluster 1 were not as likely to be diagnosed with 
ADHD than Cluster 2, but more likely than Cluster 3. Concerning side effects, parents in 
this cluster reported a possibility of regretting the treatment choice because of long-
lasting side effects. However, when considering short-lasting side effects, differences 
were seen among the parents in Cluster 1, as the majority (56.7%) reported that they 
would not regret short-lasting symptoms, while a considerable number of parents (40.7%) 
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reported possibly regretting the treatment choice due to short-lasting side effects. 
Regarding costs, the majority of parents in Cluster 1 indicated being willing to spend $15 
to $500 a month on long-term treatment. However, these parents also reported that 
insurance coverage would possibly influence their decision. Most parents in this cluster 
wanted some sessions with the treatment provider and for a therapeutic component to be 
included, but it is not required for their treatment of choice. Regarding immediate 
changes in behavior, parents in Cluster 1 indicated that immediate behavioral changes 
were not required if they had assurance of behavioral progress. The majority of parents in 
the sample reported that they would want their child to be able to discontinue treatment 
after symptoms are no longer present. Most parents in Cluster 1 wanted a treatment that 
will help their child be more aware of their ADHD symptoms. However, it is important to 
note that many parents (23.7%) in this cluster also indicated that this was not important to 
them. Regarding medication treatment, parents in Cluster 1 believed that their child may 
receive a low dose of medication (91.5%) and the majority reported being willing to have 
their child complete some sessions of brain-based treatment (66.1%). When compared to 
the other clusters, the responses of parents in Cluster 1 indicate a general openness to 
brain-based treatment. Therefore, parents in Cluster 1 are considered Brain-Based 
Parents.  
Parents in Cluster 2 were the most likely to have their child in treatment for 
ADHD and were also the most likely to have been diagnosed with ADHD themselves. 
Regarding side effects, parents in this cluster were mostly not concerned with long-
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lasting or short-lasting side effects. Parents in Cluster 2 reported being willing to spend 
$15 to $500 a month on treatment with the availability of insurance possibly influencing 
their treatment choice. Most parents in this cluster reported wanting some sessions with 
the treatment provider with a therapeutic component being welcomed but not seen as a 
requirement for their child’s treatment. Parents in Cluster 2 reported that immediate 
changes in their child’s behavior were an important factor in their decision. When 
considering continuation of treatment, although most parents reported that their child 
should not have to continue treatment after symptoms are no longer observed, many 
parents also reported that continuation of treatment was not an important factor for them. 
Parents in this cluster reported that it was important for their treatment choice to help 
their child understand his or her ADHD. Regarding medication, most parents in Cluster 2 
indicated that their child may require a high dose of medication and that they would not 
receive brain-based treatment. Therefore, parents in Cluster 2 are Medication-Based 
Parents.  
Parents in Cluster 3 were less likely to have been diagnosed with ADHD and 
more likely to not have their children in treatment. Furthermore, regarding side effects, 
parents in this cluster were more preoccupied with the side effects of treatments in 
general whether short- or long-term. Parents within this cluster were not as concerned 
with treatment cost, as they were more likely to not be influenced by cost of treatment. 
However, insurance coverage may influence their treatment choice. Cluster 3 parents 
seemed to be divided regarding sessions with the treatment provider, as they wanted 
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either weekly or some sessions with the provider. However, the majority of parents in this 
group reported that a therapeutic component to treatment was a requirement for their 
child. For parents in Cluster 3, immediate changes were not important if there was 
assurance of improvement in behavior once treatment started and most wanted the 
treatment to discontinue after behavior problems were no longer observed. Parents in 
Cluster 3 wanted their child’s treatment to help their child become aware of their 
condition of ADHD and seemed to be open to the possibilities of medication treatment 
options and brain-based treatment. Therefore, parents in Cluster 3, are Open to both 
treatment options.  
Table 2 
Chi-Square Treatment Choice Task for Parents Results for Three-Cluster Solution 
Variable Cluster 1 Cluster 2 Cluster 3 X2 p 
Long-Lasting Side Effects    71.81 <.001 
Long-lasting side effects my 
child may experience will not 
make me regret the treatment 
choice. 
6.8 64.5 24.4   
The long-lasting side effects my 
child may experience may 
make me regret the treatment 
choice. 
86.4 32.3 28.9 
                       
                               Table 2 Continued… 
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Variable Cluster 1 Cluster 2 Cluster 3 X2 p 
The long-lasting side effects my 
child may experience will 
make me significantly regret 
the treatment choice.   
6.8 3.2 46.7 
Short-Lasting Side Effects    10.53 .032 
The short-lasting side effects my 
child may experience will not 
make me regret the treatment 
choice. 
57.6 61.3 42.2   
The short-lasting side effects my 
child may experience may 
make me regret the treatment 
choice. 
40.7 38.7 44.4 
 
The short-lasting side effects my 
child may experience will 
make me significantly regret 
the treatment choice. 
1.7 0.0 13.3 
Cost    18.86 <.001 
I will spend $15 to $500 a month 
on long-term treatments. 
72.9 71.0 33.3   
Cost will not influence my 
choice of treatment. 
23.7 25.8 57.8 
                    
                                 Table 2 Continued…  
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Variable Cluster 1 Cluster 2 Cluster 3 X2 p 
I will spend over $1200 a month 
on treatment if it is less than 6 
months 
3.4 3.2 8.9 
Insurance Coverage    7.76 NS 
I will only use treatment options 
that are covered by insurance 
15.3 16.1 4.4   
Insurance coverage may 
influence my choice 
76.3 64.5 71.1 
Insurance coverage will not 
influence my choice.  
8.5 19.4 24.4 
Scientific Validity    6.82 NS 
Strong scientific validity 67.8 87.1 64.4 
Scientific validity may or may 
not influence my choice 
32.2 12.9 33.3 
I will not care about scientific 
validity 
0.0 0.0 2.2 
Sessions with Provider    59.60 <.001 
Weekly sessions with provider 1.7 9.7 48.9 
Some sessions with provider 93.2 54.8 46.7 
Minimal sessions with provider 5.1 35.5 4.4 
Therapeutic Component    48.55 <.001 
Does not matter if treatment has 
therapeutic component 
5.1 32.3 8.9 
                      
                                  Table 2 Continued…  
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Variable Cluster 1 Cluster 2 Cluster 3 X2 p 
Would like it included but not 
required 
84.7 54.8 33.3 
Therapeutic component required 10.2 12.9 57.8 
Immediate Changes    25.52 <.001 
Immediate changes in behavior 
are important 
20.3 58.1 11.1 
Immediate changes are not 
important if there is 
reassurance of behavior 
changes 
78.0 38.7 80.0 
Immediate changes in behavior 
are not important 
1.7 3.2 8.9 
Continuation of Treatment    10.14 .038 
No more treatment when 
symptoms are no longer 
observed 
61.0 38.7 40.0 
Not important if treatment 
continues after symptoms are 
no longer observed 
30.5 32.3 31.1 
Important to continue to need 
treatment  
8.5 29.0 28.9 
Awareness of Condition    17.72 .001 
Treatment to keep child unaware 
of condition 
0.0 6.5 2.2 
                                   Table 2 Continued…  
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Variable Cluster 1 Cluster 2 Cluster 3 X2 p 
Not important for child to be 
aware of condition 
23.7 0.0 4.4 
Treatment to help child be aware 
of condition 
76.3 93.5 93.3 
Medication Treatment    56.64 <.001 
No medication 1.7 0.0 26.7 
Low dose of medication 91.5 48.4 68.9 
High dose of medication 6.8 51.6 4.4 
Brain-based Treatment    27.80 <.001 
No brain-based treatment 2.8 71.0 24.4 
Some sessions of brain-based 
treatment 
66.1 29.0 55.6 
40 sessions of brain-based 
treatment 
5.1 0.0 20.0 
 
A one-way ANOVA was conducted to study Hypothesis three, which states that 
parents who score higher on the AKOS, and therefore have more knowledge of ADHD, 
are more likely to be medication avoidant. However, as shown on Table 3, there were no 
significant differences between the clusters, indicating that knowledge of ADHD does not 
influence parent treatment choice. Therefore, given that the results of this one-way 
ANOVA were not significant, this study will explore the differences between each 






Results of One-Way ANOVA on AKOS Total Score and the Three-Cluster Solution 
Variable Mean SD F ratio p 
Cluster 1 42.21 3.99 -- -- 
Cluster 2 41.23 4.01 -- -- 
Cluster 3 42.95 4.39 -- -- 
AKOS Total 42.22 4.15 1.58 .221 
 
A second Chi-Square analysis (Table 4) was completed on each question of the 
AKOS and the three-cluster solution to better understand how parents’ responses on the 
AKOS were presented within the clusters. The AKOS question 1 was significant at the 
.05 level. Parents in Cluster 1 (i.e., Brain-Based Parents) and Cluster 2 (i.e., Medication-
Based Parents) believed that most children with ADHD continue to have difficulties with 
attention when they become teenagers. However, most parents in Cluster 3 (i.e., Open 
Parents) indicated that the statement was false. Question 10 addresses how medication 
would impact school performance. Results indicate a significant difference at the .05 
level. The Brain-Based Parents and Medication-Based Parents believed the statement was 
true, while the Open parents mostly believed it was false. AKOS question 12 states that 
psychological treatments are not as effective as medication in reducing symptoms. 
Similar to the results stated above, Brain-Based and Medication-Based parents mostly 
agreed that the statement was true, while the majority of Open Parents indicated that the 
statement was false. Significance was at the .01 level. However, it is important to note 
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that almost half of the parents in the Brain-Based cluster believe that this statement is 
false. The last question to have significant differences between the clusters, AKOS 
question 13, states that medication is not as beneficial after children become adolescents 
and adults. Although the majority of parents in all three clusters responded that this 
statement is false, there are significant differences within the clusters. Specifically, all 
parents in the Medication-Based cluster indicated that the statement is false. However, 




Chi-Square Attention-Deficit/Hyperactivity Disorder Knowledge Scale (AKOS) Results for the Three-Cluster Solution 







AKOS 1: Most children with ADHD 
have problems with attention when 
they become teenagers.   
64.4/35.6 64.5/35.5 42.2/57.8 6.05 .049 
AKOS 2: Children with ADHD can be 
OK in some situations and be 
distractible and disruptive in others. 
79.7/20.3 96.8/3.2 84.4/15.6 4.76 NS 
AKOS 3: Special diets, like the Feingold 
diet, have been scientifically proven to 
improve the symptoms of most people 
with ADHD. 
17.2/82.8 25.8/74.2 20.5/79.5 .92 NS 
AKOS 4: Medical tests given in a 
psychologists’ office are necessary for 
making the diagnosis of ADHD. 
54.2/45.8 35.5/64.5 53.3/46.7 3.23 NS 
Table 4 Continued… 
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AKOS 5: Medication often reduces a 
child’s tendency to be aggressive with 
others at school. 
66.7/33.3 83.9/16.1 57.8/42.2 5.76 NS 
AKOS 6: ADHD may sometimes be 
inherited. 
93.2/6.8 93.5/6.5 100.0/0.0 3.14 NS 
AKOS 7: Almost all children with 
ADHD meet national and state 
standard for learning disabilities. 
30.5/69.5 22.3/77.4 24.4/75.6 .82 NS 
AKOS 8: Boys and girls have similar 
rates of ADHD. 
25.4/74.6 29.0/71.0 15.6/84.4 2.24 NS 
AKOS 9: Children with ADHD are 
usually brighter than those without 
ADHD. 
47.5/52.5 35.5/64.5 46.7/53.3 1.32 NS 
AKOS 10: In most cases, medication will 
help a child achieve better grades in 
school.  
64.4/35.6 77.4/22.6 48.9/51.1 6.57 .037 
Table 4 Continued…  
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AKOS 11: There is a medical test that is 
very effective in identifying children 
with ADHD. 
17.2/82.8 29.0/71.0 20.0/80.0 1.73 NS 
AKOS 12: For most children with 
ADHD, psychological treatments are 
not as effective as medication in 
improving attention and reducing 
disruptive behaviors. 
50.8/49.2 71.0/29.0 35.6/64.4 9.22 .010 
AKOS 13: The medication(s) used to 
treat ADHD are of little benefit when 
children reach adolescence or 
adulthood. 
5.1/94.9 0.0/100.0 15.6/84.4 7.30 .026 
AKOS 14: There is reliable evidence that 
ADHD is often caused by having too 
much sugar in a child’s diet. 
3.4/96.6 0.0/100.0 4.4/95.6 3.69 NS 
Table 4 Continued…  
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AKOS 15: Children who are hyperactive 
at the age of 3 almost always become 
identified as having ADHD by the age 
of 7. 
15.3/84.7 3.2/96.8 15.9/84.1 3.27 NS 
AKOS 16: There are new medications 
available that are more effective and 
safer than previous medications such 
as Ritalin. 
71.2/28.8 71.0/29.0 82.2/17.8 1.97 NS 
AKOS 17: The diagnosis of ADHD can 
be made if symptoms first develop at 
the age of 10. 





 A Principal components analysis was conducted on the Treatment Choice Task 
for Parents. On the basis of the scree test (Figure 1) and the percentage of variance 
accounted for by each factor, a five-factor solution was found to be most appropriate. 
Component 1 accounted for a total of 15.53% of the variance, component 2 accounted for 
a total of 12.19% of the variance, component 3 accounted for a total of 11.79% of the 
variance, component 4 accounted for a total of 11.42% of the variance, and component 5 
accounted for a total of 9.29% of the variance. A value for loadings of .40 was used as a 
cut off for items that did not relate to a component. All 12 items loaded on these five 
components with item 12 loading on components 4 and 5 (Table 5). Component 1 was 
interpreted to represent specific treatment components, Component 2 was interpreted to 
represent side effects, Component 3 was interpreted to represent general costs to the 
family, Component 4 was interpreted to represent scientific validity and treatment choice, 
and Component 5 was interpreted to represent awareness of condition. Results of the 
factor analysis, as seen on Table 5, supported the differentiation of each individual 
question on the Treatment Choice Task for Parents, meaning that each question measured 
different factors that can influence a parent’s choice in treatment for their child. For 
further interpretation of the five factors, a Bartlett’s test (Table 7) indicated statistical 
significance at the less than .001 level indicating that the data is suitable for a data 
reduction technique. A Varimax rotation was used (Table 8) to evaluate potential 
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correlations between the TCT-P items. Correlations were found among the items 
pertaining to each factor.  
Figure 1 
Visual Results of Scree Test 
 
Note. The scree plot presented indicates the number of factors to be use in the principal 
component analysis. The cut off to determine the factors must be an Eigenvalue above 
1.0. Therefore, five factors will be used.  
Table 5 
Results of Confirmatory Factor Analysis of the 12-Item TCT-P 
Item R2 Factor 
LT SE .737 2 
ST SE .855 2 
Table 5 Continued… 
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Cost .809 3 
Insurance Coverage .734 3 
Sci. Validity .780 4 
Sessions -.678 1 
Therapeutic Comp. .701 1 
Immediate Changes .630 1 
Conti. Of Treatment .494 1 
Awareness of Cond. .899 5 
Medication -.582 4 
Brain-Based .535/-.463 4/5 
Note. The Confirmatory Factor Analysis is used to determine which factor each item 
corresponds to. LT SE = Long-Term Side Effects; ST SE = Short-Term Side Effects 
Table 6 
Component Transformation Matrix 
Factor 1 2 3 4 5 
1 .74 .42 .28 .45 .03 
2 -.49 .48 .68 -.10 .25 
3 -.06 -.63 .59 .35 -.35 
4 .46 -.32 .32 -.67 .37 
5 .11 .29 .11 -.46 -.82 
Note. 1=Treatment components; 2=Side effects; 3=Costs; 4=Scientific validity and 
treatment choice; 5=Awareness of condition 
Table 7  
Bartlett’s Test 







Relationship Between Items in the TCT-P 
TCT-P Items 1 2 3 4 5 6 7 8 9 10 11 12 
1 LT SE -            
2 ST SE .36 -           
3 Cost .08 .01** -          
4 Insurance Coverage .16 .10 .32 - 
        
5 Sci. Validity .06 .00** -.06 .10 -        
6 Sessions  -.18 -.07 -.05* .04* -.10 -       
7 Therapeutic Comp. .22 .13 .12 -.01** .04* -.40 - 
     
8 Immediate Changes .20 .00** .10 .10 .03* -.28 .24 - 
    
9 Conti. Of Treatment -.03* .05* -.07 -.09 .06 -.14 .14 .15 -    
10 Awareness of Cond. .07 .00** .03* .02* .05* -.07 .10 .07 -.00** -   
11 Medication -.35 -.13 -.21 -.03* -.18 .22 -.21 -.14 .07 -.09 -  
12 Brain-Based .10 -.10 .07 .01** .20 -.19 .27 .15 .13 -.15 -.23 - 
Note. LT SE = Long-Term Side Effects; ST SE = Short-Term Side Effects 
**. Correlation is significant at the 0.01 level (2-tailed).  






The present study sought to investigate the factors that influence parent treatment 
choice for their children with ADHD when given choices between brain-based treatment 
options or medication-based treatment. The study also addresses parents’ views on the 
viability of brain-based treatment. Furthermore, it aims to give clarity to clinicians on 
their clients’ potential choices and the variables influencing their choices, in order to 
better market to and reach parents that are interested in or open to brain-based treatments 
for their children.  
The study investigated three hypotheses; 1) When compared to brain-based 
treatment, parents will be predominantly medication oriented due to its low cost, ease of 
administration, and their child’s quicker response to treatment; 2) Based on the findings 
by Waschbusch et al. (2011), although insignificant, a large number of parents will fall in 
the brain-based oriented group due to a high number of parents that are against the use of 
medication for their child’s ADHD; and 3) Parents who score higher on the AKOS-R 
(i.e., have more knowledge of ADHD) will be more likely to be medication avoidant.  
The results did not support hypothesis one. Medication-Based Parents (i.e., 
Cluster 2) were the smallest cluster, accounting for 22.96% of the sample, with Brain-
Based Parents (i.e., Cluster 1) being the largest cluster accounting for 43.70% of the 
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sample. The results of the autoclustering analysis indicated that the data is best 
represented in three clusters. The third cluster (i.e., Cluster 3) aligns with a group of 
parents whose responses were more diverse and spread throughout the three answer 
options given in each item of The ADHD Treatment Choice Task for Parents. These 
parents were deemed as Open to both treatment options.  
Results supported hypothesis two as a large, although insignificant, number of the 
sample fell within the Brain-Based Parent cluster, given that it was largest cluster in the 
sample. Statistically significant differences between the clusters and the responses to The 
ADHD Treatment Choice Task for Parents were noted in instances when parents 
considered the long-lasting and short-lasting side effects, the cost, sessions with the 
treatment provider, the inclusion of a therapeutic component in treatment, immediate 
changes in their child’s behavior, the continuation of treatment after the symptoms 
subsided, and the inclusion of education of their child’s condition in the treatment.  
Results did not support hypothesis 3, as no significant differences were found 
between a parent’s total AKOS score and their treatment preference. These results 
indicate that a parent having knowledge of ADHD does not necessarily influence their 
treatment choice, suggesting that parents’ choices of treatment for their children are best 
explained by factors such as cost, side effects, and specific treatment components that 
will have a direct impact on their family’s lives. Although hypothesis 3 was not 
supported, further analysis of the individual AKOS questions with the three-cluster 
solution found results worth discussing. Specifically, significant differences were found 
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between the clusters when related to questions about the continued experiences of 
symptoms into adolescences and adulthood; the impact of medication on educational 
performance and behavioral symptoms; and the benefit of medication use from childhood 
into adolescence and adulthood. The results of this analysis closely aligned with the 
cluster descriptions of Brain-Based Parents, Medication-Based Parents, and Open Parents 
from the analysis of The ADHD Treatment Choice Task for Parents. When compared to 
Medication-Based Parents, responses from Brain-Based Parents were generally of the 
belief that medication was not as helpful, although it is important to note that most 
parents within the brain-based cluster were still in favor of medications (i.e., gave a 
“True” response). Similar to the results of The ADHD Treatment Choice Task for 
Parents, the Open Parents’ responses on the AKOS were much more evenly distributed 
between the answer choices of True or False.  
Studies evaluating parent preferences of treatment components for their children 
with ADHD have begun to show the importance of parent participation, parent buy-in, 
and how they can aid in treatment adherence and effectiveness. Results of this study are 
comparable to Wymbs et al. (2016) who evaluated the parent preferences of parent 
training format. The majority of their sample indicated that they preferred a training 
format that would help them better understand their child and their problems with 
ADHD. Similarly, in the present study, the majority of parents fell in the Brain-Based 
cluster, indicating that they were most interested in a treatment option that provided them 
with at least some sessions that include a therapeutic component, as well as child-focused 
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education of ADHD. The present study also had a group of parents whose responses fell 
in a middle ground where their choices were not more specifically aligned with one 
treatment option over the other. The Open parents in the present study where in contrast 
to the study conducted by Wymbs et al., as the Minimal Information parents in their 
study were more closed off to parent trainings. The Open parents in this study reveal that 
there are groups of parents who are more open to treatment options when considering 
specific treatment components and how they fit with the family’s lifestyle in conjunction 
with treatment outcomes.  
This study is also comparable to the results of Fegert et al., (2011) who found 
regarding medication treatment, parents were most interested in a treatment where 
effectiveness lasted all-day and improved their child’s emotional and social functioning. 
The present study’s results further elaborate on Fegert et al., findings, as the results were 
able to differentiate between the type of parents who may respond in this fashion. 
Differentiating parents into groups can help practitioners address parent concerns, better 
target education, and tailor treatments to fit the family’s needs. As a result, this would 
help improve both treatment buy-in and adherence, leading to a higher likelihood of 
treatment success.  
A study by Corkum et al. (1999) assessed how parent knowledge of ADHD and 
their opinions of treatment affected their enrollment and adherence to medication-based 
and behavior-based treatments. Parents were given a modified version of the AKOS and 
then decided to participate in the 12-month randomized trial of medication or placebo and 
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parent training groups or parent support groups.  The researchers monitored treatment 
enrollment and adherence over the 12-month period. Those remaining in the study at the 
end of the 12-month period were given another modified AKOS. Results showed that 
when analyzing opinions, parents were more open to nonpharmacological treatments than 
pharmacological treatments; a higher score on the AKOS was correlated with more 
positive opinions of behavioral-based treatments versus medication-based; and higher 
AKOS scores were correlated with enrollment of treatment, adherence to medication or 
behavioral-based treatment, and was not related to knowledge of ADHD or opinions of 
treatment. Furthermore, after completion of the 12-month treatment trial, parent AKOS 
scores increased, indicating more knowledge of ADHD. Similar to Corkum et al., in the 
present study, knowledge of ADHD did not have a significant impact of parent treatment 
choice. However, Corkum et al. found that parent knowledge of ADHD does affect 
treatment enrollment and adherence to the treatment.  
The present study used methods similar to the study conducted by Waschbusch et 
al., (2011). The researchers used a discrete choice task with descriptions of treatments 
and parents chose the treatment they would be mostly likely to choose for their child with 
ADHD. Results of the Waschbusch et al. study presented two groups of parents, 
Medication Avoidant and Outcome Oriented parents. The present study also found that 
parents’ treatment choices and the factors that influenced their choices can categorize 
parents into descriptive groups. Furthermore, the present study also determined that when 
presented with treatment information and given options, parents were largely predicted to 
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choose treatments that focus more on behavioral modification or a combination of 
behavioral intervention and medications instead of strictly medication-based treatment.  
When considering brain-based treatments, parent perceptions and their 
expectations also play an important role. A study conducted by deBeus and Kaiser (2011) 
hypothesized that children in a neurofeedback treatment group would experience ADHD 
symptoms improved, as measured by parent and teacher rating scales and formal ADHD 
assessments using the IVA CPT, when compared to a placebo group. Results indicated 
that teacher reports showed improvement in behavior after the neurofeedback treatment. 
However, there were no changes in parent ratings between the treatment and placebo 
groups. This indicates that parents in the placebo and the neurofeedback treatment 
conditions, both, rated their child as improving. deBeus and Kaiser attributed this finding 
to an expectancy bias. This highlights the significant role that a parent’s perception plays 
in the treatment of their child’s symptoms. This study also shows that parental 
expectations can influence a parent’s perception of how effective the treatment is.  
Recent clinical practice guidelines as described by Shah et al. (2019), include the 
need to evaluate parents’ perceptions concerning treatment, consider their treatment 
preferences, and consider the family’s current circumstance and resources in order to 
recommend a treatment that best fits their needs, resources, and lifestyle. They stress the 
importance of a “therapeutic alliance,” which is done by holding positive regard and 
respect for parents’ and families’ opinions and concerns about certain treatments. Shah 
and colleagues also address the importance of psychoeducation with parents and their 
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children. They recommend an average of two to three sessions of psychoeducation that 
are also individualized for the family being served. Specifically, they state that clinicians 
should focus on providing detailed information on the core symptoms of ADHD and the 
etiological factors of ADHD such as genetic and environment components. They also 
recommend addressing parental guilt or shame; prevalent misconceptions of ADHD; 
descriptions of pharmacological and nonpharmacological treatment options along with 
their risks and benefits, and possible outcomes if treatment is sought or if treatment is 
either rejected or inconsistent; and the effect of comorbid disorders if present in the child. 
When considering brain-based treatments, many of these topics are addressed in the 
multiple sessions with the treatment provider. Clinical practice guidelines were proposed 
by Micoulaud-Franchi et al. (2015). In their review, they suggest that, although optimum 
spacing has not yet been defined, N.F. is usually completed in 20-30 sessions, once to 
three times per week. They also note the importance of continued discussions with the 
patient, and for the purposes of this present study, discussions with the family and child. 
These discussions should include detailed descriptions of the treatment session before 
starting, information to sustain motivation during the session, and an explanation of what 
to expect after session completion. These proposed practice guidelines for neurofeedback 
therapy allow for optimal therapeutic relationship and rapport building, psychoeducation, 
and continued communication with parents and children about how the treatment is 
progressing toward their goals, any proposed changes, and overall opinions of treatment 
options. The development of clinical guidelines in the field of N.F. is critical to its 
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perceived and actual effectiveness; and would, in turn, improve parent buy-in for N.F. as 
a treatment option for their children. Furthermore, implementation of set guidelines can 
aid in N.F. becoming more widely accessible through more reasonable costs and 
insurance coverage, which as noted in the present study cost has a significant influence 
on parents’ treatment choices.  
This study highlights that when offered information on treatment choices, parents 
are more influenced by treatment components, costs, therapeutic sessions, education of 
ADHD, and behavioral modification than they are by their knowledge of ADHD. This is 
of use to clinicians building a brain-based treatment practice for the purposes of 
marketing their treatment, gauging parents’ openness to and/or interest in brain-based 
treatments, and understanding the specifics driving treatment choice by parents. 
Clinicians can use the information from the present study to educate parents on brain-
based treatments and find methods to increase the scientific validity of N.F., increase 
access to insurance coverage, and provided more affordable treatment options to parents 
for their children with ADHD.  
Throughout the course of the study, parent participants expressed concerns with 
the survey. Some parents reported starting the survey but not finishing as they believed 
that the survey forced answers between two choices (specifically in reference to the 
AKOS.) Other parents reported that the wording was either confusing or strongly biased 
toward brain-based treatment. Comments from parents suggest that when answering the 
survey questions, parents did so in reference to their children’s’ current course of 
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treatment, rather than the treatment options described in the survey itself (as designed). 
For example, one parent had difficulty answering questions because their child is 
currently receiving both behavioral and medication treatment and they could not make an 
appropriate choice. These concerns from parents indicates that both the AKOS and 
Treatment Choice Task for Parents should be heavily reviewed and modified to limit 
perceived and actual bias and to clarify instructions on how the survey should be 
completed (i.e., parents are to consider choice options based on the treatments described 
in the survey, and not based off of treatments their child currently receives). Regarding 
bias, this study may have been influenced by researcher bias, as the primary investigators 
have had extensive experience in the research and clinical use of brain-based treatment 
techniques. The descriptions may also present a more positive description of 
neurofeedback than is warranted. As reported by Micoulaud-Franchi et al (2015), 
neurofeedback has not been deemed a therapy that can be used, solely, to treat mental and 
brain disorders, but rather in conjunction with other treatments. While they note that 
promising results have been found in controlled, randomized, and blinded studies; a 
plethora of studies with faulty neurofeedback protocols, lack of appropriate comparison 
groups, and lack of control and randomization have made it difficult to study its true 
effectiveness.  Furthermore, the present study did not document important demographic 
information from parents concerning their child’s ADHD (e.g., how long they have 
carried the diagnosis). Information on their child’s current treatment, such as whether 
they are receiving medication treatment, if so, what type of medication is being used, was 
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not collected. Information from parents on their previous experiences with ADHD 
treatments whether behavioral or pharmacological were also not included in the 
demographic’s questionnaire.  
Replication of this study is recommended. Stronger measures should be 
implemented to accurately evaluate how parent treatment preferences can affect treatment 
efficacy, and to assess parents’ opinions on the feasibility of brain-based treatments. Due 
to the frustration parents experienced as they completed the choice task, future studies 
should consider including a statement that instructs parents to choose their preferences 
based, solely, on the treatment options in the survey, rather than comparing to their 
child’s current treatment. Future studies should also evaluate the efficacy of using the 
AKOS, as it may not be an accurate representation of an individual’s knowledge of 
ADHD. This study recommends that the AKOS be revised or updated to include most up-
to-date best practices and clinical information. The ADHD Treatment Choice Task for 
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List of Social Media Parent Groups Used for Survey Distribution 
ADDitude – ADHD Support Group for Parents 
ADHD/ADD Parent Support Group 
ADHD Parent Support 
Support Group For Parents Of Kids With ADHD, ODD And Other Behavioral Issue 
ADHD Texas Kids Support Group For Parents 
Moms With ADHD/ADD Kids 
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Descriptive Statistics for the Final Sample (N = 137)  
Variable  N % 
Gender   
Female  134 97.8% 
Male  3 2.2% 
































Formally Diagnosed with ADHD  23 16.8% 
Child receiving treatment for ADHD 










ADHD Treatment Choice Task for Parents 
 
Descriptions of Treatment Components Presented to Parents 
 
Treatment 1: Medication 
 Description: There are multiple medication options for the treatment of ADHD. 
The two main types are stimulant and non-stimulant medications. Stimulant medications 
can be classified in two groups, methylphenidates and amphetamines. Non-stimulant 
medications are classified as tricyclic antidepressants, non-tricyclic antidepressants, 
specific norepinephrine reuptake inhibitors, and non-schedule stimulants.  
 Possible Outcomes: According to many research studies and clinical trials, 
medication use for management of ADHD symptoms can decrease hyperactivity and 
impulsivity and increased focus and concentration for an extended period of time. The 
decrease of symptoms can lead to improvements in academic, occupational, and social 
performance.  
 Side Effects: For some individuals medication side effects can be troubling and 
long lasting. The most common side effects of stimulant medications include difficulty 
falling asleep, decrease in appetite, headaches, stomach aches, irritability or a sudden or 
more severe presentation of ADHD symptoms. The most common side effects of non-




 Cost: Most medications are available in generic or name brand form. Depending 
on the form chosen, medications can range in monthly costs between $15 to $500 given 
that most insurance covers this type of treatment. Medication management typically 
requires that the individual use medications for many years.  
Treatment Option 2: Brain-Based Treatment 
 Description: Research has shown emerging but promising results on the use of 
brain-based treatment for ADHD. Neurofeedback is one widely researched technique that 
consists of training pre-determined brain-wave frequencies using visual or auditory 
rewards. A cap is placed on the head which measures electrical frequencies in the brain 
and displays the frequencies on a software program.  
 Possible Outcomes: Brain-based treatment of ADHD, such as Neurofeedback, are 
considered “experimental.” Some research has suggested that this technique can create 
long lasting changes in the brain that help the individual manage impulses and increase 
attention and focus, which can positively influence academic, occupational, and social 
performance. Techniques such as Neurofeedback have also been found to increase sleep 
quality and mood stability. 
 Side Effects: The most common side effects of brain-based treatment are mild and 
only last for few hours after each session; these include, headaches, dizziness, and 
redness at the site of the electrodes.  
 Cost: Most insurance providers do not cover the cost of brain-based treatments 
such as Neurofeedback. The cost of Neurofeedback, per session, can range from $100 to 
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$300, about $1200 monthly. Neurofeedback is usually not covered by insurance. Brain-
based therapy sessions are not a life-long treatment option. Most clients are able to stop 
treatment after 40 sessions or after 5 months but may need “booster” sessions every few 






The ADHD Treatment Choice Task for Parents 
 
Side effects: 
Long-lasting side effects 
(i.e., loss of appetite, 
headaches, irritability) 
my child may experience 
will not make me regret 
the treatment choice. 
The long-lasting side 
effects (i.e., loss of 
appetite, headaches, 
irritability) my child may 
experience may make me 
regret the treatment 
choice. 
The long-lasting side 
effects (i.e., loss of 
appetite, headaches, 
irritability) my child may 
experience will make me 
significantly regret the 
treatment choice.   
 
The short-lasting side 
effects (i.e., headaches, 
dizziness, redness at 
electrode site) my child 
may experience will not 
make me regret the 
treatment choice. 
The short-lasting side 
effects (i.e., headaches, 
dizziness, redness at 
electrode site) my child 
may experience may 
make me regret the 
treatment choice. 
The short-lasting side 
effects (i.e., headaches, 
dizziness, redness at 
electrode site) my child 
may experience will make 
me significantly regret 




I will spend $15 to $500 a 
month on long-term 
treatments for my child. 
Cost will not influence 
my choice of treatment 
for my child. 
I will spend over $1200 a 
month as long as the 
treatment does not last 
longer than 6 months. 
 
I will only use a 
treatment option for my 
child that is covered by 
my insurance.  
Insurance coverage may 
influence my choice of 
treatment.  
Insurance coverage will 




Scientific Validity:  
 
I will only use a 
treatment option for my 
child that has strong 
scientific evidence.  
Scientific evidence may 
or may not influence my 
choice of treatment.   
I will not care about 





Treatment Sessions:  
 
I would like my child’s 
treatment to require 
weekly sessions with the 
provider. 
I would like the 
treatment to have some 
sessions with the 
provider, but it is not 
required. 
I would prefer a 
treatment with minimal 




It does not matter if my 
child’s treatment includes 
a therapeutic component. 
I would like my child’s 
treatment to include a 
therapeutic component, 
but it is not required. 
My child’s treatment 




It is important that my 
child will experience 
immediate changes in 
behavior after starting 
treatment. 
It is NOT important that 
my child will experience 
immediate changes in 
behavior after starting 
treatment, as long as I get 
assurance that benefits 
will come later. 
It is NOT important that 
my child will experience 
immediate changes in 
behavior after starting 
treatment. 
 
Continuation of Treatment: 
When symptoms are no 
longer observed, it is 
important that my child 
will not continue 
treatment (other than 
some booster sessions). 
When symptoms are no 
longer observed, it is 
NOT important if my 
child continues to need 
treatment. 
When symptoms are no 
longer observed, it is 
important that my child 
continue to need 
treatment regularly for 
many years. 
 
Child Awareness:   
It is important that I 
choose a treatment that 
keeps my child unaware 
of his/her condition. 
It is not important if my 
child is aware of his/her 
condition. 
It is important that I 
choose a treatment that 
helps my child be aware 
of his/her condition.  
 
Treatment components:  
My child will not get 
medication. 
My child will get a low 
dose of medication. 
My child will get a high 




My child will not attend 
brain-based treatment 
sessions. 
My child will attend some 
sessions of brain-based 
treatment. 
My child will attend 40 
sessions of brain-based 
treatment. 
 
My child will not attend 
behavioral therapy 
sessions 
My child will attend some 
sessions of behavioral 
therapy 
My child will regularly 











Below is a series of true-false statements. Click True if you believe the state is true or 
correct. Click False is you think the statement is false or incorrect.  
Note: Please do not search for information on these questions. It is very important to get 
your current understanding.  
 
1. Most children with ADHD have problems with attention when they 
become teenagers T F 
2. Children with ADHD can be OK in some situations (such as at 
home) and can be distractible and disruptive in others (such as at 
school). 
T F 
3. Special diets, like the Feingold diet, have been scientifically proven 
to improve the symptoms of most people with ADHD.  T F 
4. Medical tests given in a psychologists’ office are necessary for 
making the diagnosis of ADHD T F 
5. Medication often reduces a child’s tendency to be aggressive with 
others at school.  T F 
6. ADHD may sometimes be inherited (passed along in the family). T F 
7. Almost all children with ADHD meet national and state standard for 
learning disabilities.  T F 
8. Boys and girls have similar rates of ADHD T F 
9. Children with ADHD are usually brighter than those without 
ADHD T F 
10.  In most cases, medication will help a child achieve better grades in 
school T F 
11.  There is a medical test that is very effective in identifying children 
with ADHD. T F 
12.  For most children with ADHD, psychological treatments are not as 
effective as medication in improving attention and reducing 
disruptive behaviors.  
T F 
13.  The medication(s) used to treat ADHD are of little benefit when 
children reach adolescence or adulthood. T F 
14.  There is reliable evidence that ADHD is often caused by having too 
much sugar in a child’s diet. T F 
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15.  Children who are hyperactive at the age of 3 almost always become 
identified as having ADHD by the age of 7.  T F 
16.  There are new medications available that are more effective and 
safer than previous medications such as Ritalin T F 
17.  The diagnoses of ADHD can be made is symptoms first develop at 






Results of Pilot Study on the TCT-P  
 
Table 1  
 
Results of Pilot Study on The ADHD Treatment Choice Task for Parents 
Percentage of pilot participants responses 
Choice Item Percentage 
Side Effects  
The long-lasting side effects (i.e., loss of appetite, headaches, 
irritability) my child may experience may make me significantly 
regret the treatment choice. 
90% 
 
The long-lasting side effects (i.e., loss of appetite, headaches, 




The short-lasting side effects (i.e., headaches, dizziness, redness at 
electrode site) my child may experience will make me significantly 
regret the treatment choice. 
30% 
 
The short-lasting side effects (i.e., headaches, dizziness, redness at 
electrode site) my child may experience may make me regret the 
treatment choice. 
60% 
The short-lasting side effects (i.e., headaches, dizziness, redness at 





Table 1 Continued… 
Cost/Insurance Coverage 
 
I will spend over $1200 a month as long as the treatment does not last 
longer than 6 months. 
10% 
Cost will not influence my choice of treatment for my child. 40% 
I will spend $15 to $500 a month on long-term treatments for my child. 50% 
Insurance coverage will not influence my choice of treatment. 30% 
Insurance coverage may influence my choice of treatment. 70% 
Scientific Validity  
Scientific evidence may or may not influence my choice of treatment. 10% 
I will only use a treatment option for my child that has strong scientific 
evidence. 
90% 
Treatment Sessions  
I would prefer a treatment with minimal sessions with the provider 30 
I would like my child’s treatment to require weekly sessions with the 
provider. 
30% 
I would like the treatment to have some sessions with the provider, but 
it is not required. 
40% 
Therapeutic Component  
It does not matter if my child’s treatment includes a therapeutic 
component. 
20% 
My child’s treatment must include a therapeutic component. 20% 
I would like my child’s treatment to include a therapeutic component, 
but it is not required. 
60% 
Immediate Changes  
It is NOT important that my child will experience immediate changes in 




Table 1 Continued… 
It is NOT important that my child will experience immediate changes in 
behavior after starting treatment, as long as I get assurance that 
benefits will come later. 
80% 
Continuation of Treatment  
When symptoms are no longer observed, it is NOT important if my 
child continues to need treatment. 
22.2% 
 
When symptoms are no longer observed, it is important that my child 
continue to need treatment regularly for many years. 
33.3% 
 
When symptoms are no longer observed, it is important that my child 
will not continue treatment (other than some booster sessions). 44.4% 
Child Awareness  
It is not important if my child is aware of his/her condition. 10% 
It is important that I choose a treatment that helps my child be aware of 
his/her condition. 
90% 
Treatment Component  
My child will not get medication. 22.2% 
My child will get a low dose of medication. 77.7% 
My child will attend 40 sessions of brain-based treatment. 22.2% 





Chi-Square Results for the Four Cluster Solution 
Table 1 
Chi-Square Treatment Choice Task for Parents Results for Four Cluster Solution 







N=42 X2 p 
Long-Lasting Side Effects     65.95 <.001 
Long-lasting side effects my child 
may experience will not make 
me regret the treatment choice. 
14.3 57.1 47.8 4.8 
  
The long-lasting side effects my 
child may experience may make 
me regret the treatment choice. 
83.3 0.0 47.8 66.7 
Table 1 Continued… 
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N=42 X2 p 
The long-lasting side effects my 
child may experience will make 
me significantly regret the 
treatment choice.   
2.4 42.9 4.3 28.6 
  
Short-Lasting Side Effects     53.73 <.001 
The short-lasting side effects my 
child may experience will not 
make me regret the treatment 
choice. 
78.6 75.0 34.8 23.8 
  
The short-lasting side effects my 
child may experience may make 
me regret the treatment choice. 
19.0 7.1 65.2 73.8 
The short-lasting side effects my 
child may experience will make 
me significantly regret the 
treatment choice. 
2.4 17.9 0.0 2.4 
Table 1 Continued… 
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N=42 X2 p 
Cost     58.66 <.001 
I will spend $15 to $500 a month 
on long-term treatments. 
76.2 0.0 95.7 61.9 
  
Cost will not influence my choice 
of treatment. 
21.4 85.7 4.3 33.3 
I will spend over $1200 a month 
on treatment if it is less than 6 
months 
2.4 14.3 0.0 4.8 
Insurance Coverage     20.77 .002 
I will only use treatment options 
that are covered by insurance 
23.8 0.0 17.4 4.8 
  
Insurance coverage may influence 
my choice 
64.3 64.3 69.6 85.7 
Insurance coverage will not 
influence my choice.  
11.9 35.7 13.0 9.5 
Scientific Validity     9.21 NS 
                                        Table 1 Continued… 
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N=42 X2 p 
Strong scientific validity 78.6 78.6 69.6 59.5 
Scientific validity may or may not 
influence my choice 
21.4 17.9 30.4 40.5 
I will not care about scientific 
validity 
0.0 3.6 0.0 0.0 
Sessions with Provider     26.79 <.001 
Weekly sessions with provider 4.8 17.9 13.0 38.1 
Some sessions with provider 90.5 67.9 56.5 57.8 
Minimal sessions with provider 4.8 14.3 30.4 7.1 
Therapeutic Component     54.69 <.001 
Does not matter if treatment has 
therapeutic component 
0.0 14.3 39.1 9.5 
Would like it included but not 
required 
95.2 53.6 52.2 35.7 
Therapeutic component required 4.8 32.1 8.7 54.8 
Immediate Changes     35.24 <.001 
                                             Table 1 Continued… 
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N=42 X2 p 
Immediate changes in behavior 
are important 
26.2 32.1 65.2 0.0 
Immediate changes are not 
important if there is reassurance 
of behavior changes 
71.4 60.7 30.4 95.2 
Immediate changes in behavior 
are not important 
2.4 7.1 4.3 4.8 
Continuation of Treatment     13.78 .032 
No more treatment when 
symptoms are no longer 
observed 
66.7 53.6 39.1 33.3 
Not important if treatment 
continues after symptoms are no 
longer observed 
26.2 21.4 30.4 42.9 
Important to continue to need 
treatment  
7.1 25.0 30.4 23.8 
                     Table 1 Continued… 
112 
 







N=42 X2 p 
Awareness of Condition     11.05 NS 
Treatment to keep child unaware 
of condition 
0.0 7.1 4.3 0.0 
Not important for child to be 
aware of condition 
14.3 7.1 0.0 19.0 
Treatment to help child be aware 
of condition 
85.7 85.7 95.7 81.0 
Medication Treatment     25.84 <.001 
No medication 0.0 25.0 0.0 14.3 
Low dose of medication 92.9 53.6 65.2 73.8 
High dose of medication 7.1 21.4 34.8 11.9 
Brain-based Treatment     44.55 <.001 
No brain-based treatment 26.2 35.7 95.7 16.7 
Some sessions of brain-based 
treatment 
66.7 53.6 4.3 69.0 
40 sessions of brain-based 
treatment 
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